Compounds > hydroxyurea
Page last updated: 2024-10-28

hydroxyurea and Thrombocythemia, Essential

hydroxyurea has been researched along with Thrombocythemia, Essential in 305 studies

Thrombocythemia, Essential: A clinical syndrome characterized by repeated spontaneous hemorrhages and a remarkable increase in the number of circulating platelets.

Research Excerpts

ExcerptRelevanceReference
"Hydroxyurea (HU) treatment of patients with essential thrombocythemia (ET), polycythemia vera (PV), and primary myelofibrosis (PMF) (MPNs) normalizes elevated blood cell counts within weeks in the large majority of patients."9.41Data-driven analysis of the kinetics of the JAK2V617F allele burden and blood cell counts during hydroxyurea treatment of patients with polycythemia vera, essential thrombocythemia, and primary myelofibrosis. ( Andersen, M; Dam, MJB; Hasselbalch, HC; Kjaer, L; Knudsen, TA; Ottesen, JT; Pedersen, RK; Skov, V, 2021)
"Therapeutic options for patients with polycythemia vera (PV) and essential thrombocythemia (ET) resistant or intolerant to hydroxyurea are limited."9.19Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea. ( Alvarez-Larrán, A; Ancochea, A; Angona, A; Antelo, ML; Bellosillo, B; Besses, C; Burgaleta, C; Cervantes, F; Durán, MA; Ferrer-Marín, F; Gómez, M; Gómez-Casares, MT; Hernández-Boluda, JC; Marcote, B; Martínez-Avilés, L; Martínez-Trillos, A; Mata, MI; Senín, A; Vicente, V; Xicoy, B, 2014)
"Hydroxyurea (HU) has traditionally been the first-line treatment for patients with polycythemia vera (PV) or essential thrombocythemia (ET) at high risk for vascular complications."8.90Therapeutic options for patients with polycythemia vera and essential thrombocythemia refractory/resistant to hydroxyurea. ( Newberry, KJ; Sever, M; Verstovsek, S, 2014)
"Hydroxyurea (HU) is effective in controlling thrombocytosis while reducing the risk of thrombosis in essential thrombocythemia (ET), polycythemia vera (PV) and myelofibrosis (MF)."8.83Leg ulcers in elderly on hydroxyurea: a single center experience in Ph- myeloproliferative disorders and review of literature. ( Fabris, F; Luzzatto, G; Randi, ML; Ruzzon, E; Scandellari, R; Tezza, F, 2006)
"Hydroxyurea is an old drug that is often used to control essential thrombocythemia and polycythemia vera in patients with high-risk disease."8.83Hydroxyurea: The drug of choice for polycythemia vera and essential thrombocythemia. ( Dingli, D; Tefferi, A, 2006)
"To determine the prevalence, clinical outcomes, and factors associated with hydroxyurea (HU) resistance or intolerance among polycythemia vera (PV) and essential thrombocythemia (ET) patients."8.12Prevalence and clinical outcomes of polycythemia vera and essential thrombocythemia with hydroxyurea resistance or intolerance. ( Chai-Adisaksopha, C; Chiaranairungrot, K; Hantrakool, S; Kaewpreechawat, K; Norasetthada, L; Pagowong, N; Piriyakhuntorn, P; Rattanathammethee, T; Rattarittamrong, E; Sajai, C; Sukarat, N; Tantiworawit, A, 2022)
"ABSTRACTBackground: Current guidelines recommend hydroxyurea (HU) as frontline therapy for patients with high-risk essential thrombocythemia (ET) to prevent thrombosis."7.91Impact of Hydroxyurea on Survival and Risk of Thrombosis Among Older Patients With Essential Thrombocythemia. ( Davidoff, AJ; Giri, S; Gore, SD; Huntington, SF; Ma, X; Podoltsev, NA; Wang, R; Wang, X; Zeidan, AM; Zhu, M, 2019)
" We present a unique case of ET causing extensive arterial thromboembolism, despite being on adequate antithrombotic agents including warfarin and aspirin."7.85Medical Management of Extensive Arterial Thromboembolism in a Patient with Essential Thrombocythemia and Warfarin Failure. ( Ahmed, AK; Skeik, N; Youssef, A, 2017)
"The onset of a dermatomyositis-like rash and persistent skin ulcers during long-term treatment with hydroxyurea is a very rare event that has not been fully described in the literature."7.75[Multiple, painful, treatment-resistant leg ulcers associated with dermatomyositis-like lesions over the interphalangeal joints induced by hydroxyurea]. ( Guillén-Barona, C; Martorell-Calatayud, A; Nagore-Enguídanos, E; Requena, C, 2009)
"We report the case of a 65-year-old woman who developed symptoms of spinal cord compression due to a spinal meningioma after 10 years of treatment with hydroxyurea (1000 mg/day) for essential thrombocytemia."7.71Spinal meningioma during hydroxyurea therapy. A paradoxycal case report. ( Giordano, F; Pagni, CA; Savarino, A, 2002)
"In polycythemia vera (PV), treatment with chlorambucil and radioactive phosphorus (p32) increases the risk of leukemic transformation from 1% to 13-14%."7.69Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. ( Fisher, SG; Godwin, J; Nand, S; Stock, W, 1996)
"Thrombotic events and disease progression were infrequent in both arms, whereas grade 3/4 adverse events were more frequent with PEG (46% vs 28%)."7.11A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia. ( Arango Ossa, JE; Arcasoy, MO; Bacigalupo, A; Barbui, T; Berenzon, D; Catchatourian, R; De Stefano, V; Dueck, AC; Ewing, J; Farnoud, N; Goldberg, JD; Harrison, CN; Hoffman, R; Kessler, CM; Kiladjian, JJ; Kosiorek, HE; Kremyanskaya, M; Leibowitz, DS; Levine, MF; Marchioli, R; Mascarenhas, J; McGovern, E; McMullin, MF; Mead, AJ; Mesa, RA; Nagler, A; Najfeld, V; O'Connell, CL; Penson, AV; Prchal, JT; Price, L; Rambaldi, A; Rampal, RK; Rondelli, D; Salama, ME; Sandy, L; Silver, RT; Tognoni, G; Tripodi, J; Vannucchi, AM; Weinberg, RS; Winton, EF; Yacoub, A, 2022)
"Hydroxyurea (HU) treatment of patients with essential thrombocythemia (ET), polycythemia vera (PV), and primary myelofibrosis (PMF) (MPNs) normalizes elevated blood cell counts within weeks in the large majority of patients."5.41Data-driven analysis of the kinetics of the JAK2V617F allele burden and blood cell counts during hydroxyurea treatment of patients with polycythemia vera, essential thrombocythemia, and primary myelofibrosis. ( Andersen, M; Dam, MJB; Hasselbalch, HC; Kjaer, L; Knudsen, TA; Ottesen, JT; Pedersen, RK; Skov, V, 2021)
"At present, the treatment of polycythemia vera (PV) and essential thrombocythemia (ET) is still largely supportive and symptomatic."5.39Homoharringtonine is an effective therapy for patients with polycythemia vera or essential thrombocythemia who have failed or were intolerant to hydroxycarbamide or interferon-α therapy. ( Ding, B; Li, Y; Zhu, J, 2013)
"Twenty-one polycythemia vera, 28 essential thrombocythemia, eight secondary erythrocytosis, and 30 controls were studied."5.37Differential expression of JAK2 and Src kinase genes in response to hydroxyurea treatment in polycythemia vera and essential thrombocythemia. ( Albizua, E; Ayala, R; Barrio, S; Besses, C; Espinet, B; Florensa, L; Gallardo, M; Jimenez, A; Martinez-Lopez, J; Puigdecanet, E; Rapado, I; Rueda, D; Sanchez-Espiridion, B, 2011)
"Hydroxyurea can cause reversible inhibition of spermatogenesis and result in primary infertility."5.34Hydroxyurea therapy: a rare cause of reversible azoospermia. ( Barua, JM; Hafeez, A; Hughes, A; Masood, J, 2007)
"Hydroxyurea is a hydroxylated derivate of urea commonly used in the treatment of various hematologic disorders."5.33Leg ulcer in a patient associated with hydroxyurea therapy. ( Dissemond, J; Franckson, T; Goos, M; Hoeft, D; Knab, J; Kroger, K, 2006)
" The dosage of HU was decreased to 500 mg daily when the platelet counts were found to be within normal levels."5.31Leg ulcers and hydroxyurea: report of three cases with essential thrombocythemia. ( Adigüzel, C; Cömert, A; Demirçay, Z, 2002)
"Drug-induced fever is a frequent (3-5% of all adverse effects) but under recognized adverse effect of several drugs."5.30[Drug-induced fever caused by hydroxyurea. Apropos of 3 new cases]. ( Allochon, Y; Blanc, M; Evreux, JC; Gallant, C; Monier, JM; Vial, T, 1998)
"Therapeutic options for patients with polycythemia vera (PV) and essential thrombocythemia (ET) resistant or intolerant to hydroxyurea are limited."5.19Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea. ( Alvarez-Larrán, A; Ancochea, A; Angona, A; Antelo, ML; Bellosillo, B; Besses, C; Burgaleta, C; Cervantes, F; Durán, MA; Ferrer-Marín, F; Gómez, M; Gómez-Casares, MT; Hernández-Boluda, JC; Marcote, B; Martínez-Avilés, L; Martínez-Trillos, A; Mata, MI; Senín, A; Vicente, V; Xicoy, B, 2014)
" As compared with hydroxyurea plus aspirin, anagrelide plus aspirin was associated with increased rates of arterial thrombosis (P=0."5.11Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. ( Bareford, D; Buck, G; Campbell, PJ; East, CL; Green, AR; Grigg, AP; Harrison, CN; Reilly, JT; Revell, P; van der Walt, JD; Wheatley, K; Wilkins, BS; Woodcock, BE, 2005)
"We have previously demonstrated that hydroxyurea (HU) reduces the rate of vascular complications in patients with essential thrombocythaemia (ET) at high risk of thrombosis."5.09Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial. ( Barbui, T; Finazzi, G; Rodeghiero, F; Ruggeri, M, 2000)
" The aim of this study was to meta-analyze currently available data comparing anagrelide to hydroxyurea for reduction of rates of thrombosis, bleeding and death among patients with ET."4.91Anagrelide compared with hydroxyurea in essential thrombocythemia: a meta-analysis. ( Chai-Adisaksopha, C; Garcia, D; Samuelson, B, 2015)
"Hydroxyurea (HU) has traditionally been the first-line treatment for patients with polycythemia vera (PV) or essential thrombocythemia (ET) at high risk for vascular complications."4.90Therapeutic options for patients with polycythemia vera and essential thrombocythemia refractory/resistant to hydroxyurea. ( Newberry, KJ; Sever, M; Verstovsek, S, 2014)
" Results of the first phase III trial (PT1) that compared anagrelide/aspirin with hydroxyurea/aspirin have sparked an intense discussion, given that the combination of anagrelide and aspirin causes more bleeding complications in the gastrointestinal tract."4.83Anagrelide: what was new in 2004 and 2005? ( Petrides, PE, 2006)
"Hydroxyurea (HU) is effective in controlling thrombocytosis while reducing the risk of thrombosis in essential thrombocythemia (ET), polycythemia vera (PV) and myelofibrosis (MF)."4.83Leg ulcers in elderly on hydroxyurea: a single center experience in Ph- myeloproliferative disorders and review of literature. ( Fabris, F; Luzzatto, G; Randi, ML; Ruzzon, E; Scandellari, R; Tezza, F, 2006)
"Hydroxyurea is an old drug that is often used to control essential thrombocythemia and polycythemia vera in patients with high-risk disease."4.83Hydroxyurea: The drug of choice for polycythemia vera and essential thrombocythemia. ( Dingli, D; Tefferi, A, 2006)
" In this regard, a controlled clinical trial has previously demonstrated the efficacy of hydroxyurea in reducing the risk of thrombosis in high-risk patients with essential thrombocythemia (ET)."4.82A critical review of anagrelide therapy in essential thrombocythemia and related disorders. ( Dingli, D; Tefferi, A, 2005)
" Randomized studies have shown that the risk of thrombosis was significantly reduced in ET with the use of hydroxyurea (HU) and in PV with the use of chlorambucil or 32P."4.80Treatment of polycythaemia vera and essential thrombocythaemia. ( Silverstein, MN; Tefferi, A, 1998)
"To determine the prevalence, clinical outcomes, and factors associated with hydroxyurea (HU) resistance or intolerance among polycythemia vera (PV) and essential thrombocythemia (ET) patients."4.12Prevalence and clinical outcomes of polycythemia vera and essential thrombocythemia with hydroxyurea resistance or intolerance. ( Chai-Adisaksopha, C; Chiaranairungrot, K; Hantrakool, S; Kaewpreechawat, K; Norasetthada, L; Pagowong, N; Piriyakhuntorn, P; Rattanathammethee, T; Rattarittamrong, E; Sajai, C; Sukarat, N; Tantiworawit, A, 2022)
"ABSTRACTBackground: Current guidelines recommend hydroxyurea (HU) as frontline therapy for patients with high-risk essential thrombocythemia (ET) to prevent thrombosis."3.91Impact of Hydroxyurea on Survival and Risk of Thrombosis Among Older Patients With Essential Thrombocythemia. ( Davidoff, AJ; Giri, S; Gore, SD; Huntington, SF; Ma, X; Podoltsev, NA; Wang, R; Wang, X; Zeidan, AM; Zhu, M, 2019)
" We present a unique case of ET causing extensive arterial thromboembolism, despite being on adequate antithrombotic agents including warfarin and aspirin."3.85Medical Management of Extensive Arterial Thromboembolism in a Patient with Essential Thrombocythemia and Warfarin Failure. ( Ahmed, AK; Skeik, N; Youssef, A, 2017)
"Patients in the interferon alpha 2 b group achieved higher rates of hematologic and molecular remission than patients in the hydroxyurea group, with a lower incidence of thrombosis."3.80Interferon apha 2b for treating patients with JAK2V617F positive polycythemia vera and essential thrombocytosis. ( Duan, YC; Zhang, ZR, 2014)
" He was thought to have had an embolic stroke and was initially treated with warfarin."3.80Repeated episodes of ischemic stroke over a short period in a patient with essential thrombocythemia on anticoagulant therapy. ( Hirano, T; Isoda, K; Ito, K; Naganuma, M; Nishi, S, 2014)
"The onset of a dermatomyositis-like rash and persistent skin ulcers during long-term treatment with hydroxyurea is a very rare event that has not been fully described in the literature."3.75[Multiple, painful, treatment-resistant leg ulcers associated with dermatomyositis-like lesions over the interphalangeal joints induced by hydroxyurea]. ( Guillén-Barona, C; Martorell-Calatayud, A; Nagore-Enguídanos, E; Requena, C, 2009)
"We analyzed the effect of hydroxyurea on the JAK2V617F allelic ratio (%JAK2V617F), measured in purified blood granulocytes, of patients with polycythemia vera and essential thrombocythemia."3.74Frequent reduction or absence of detection of the JAK2-mutated clone in JAK2V617F-positive patients within the first years of hydroxyurea therapy. ( Cleyrat, C; Duval, A; Girodon, F; Hermouet, S; Lafont, I; Maynadié, M; Mounier, M; Santos, FD; Schaeffer, C; Vidal, A, 2008)
"We report the case of a 65-year-old woman who developed symptoms of spinal cord compression due to a spinal meningioma after 10 years of treatment with hydroxyurea (1000 mg/day) for essential thrombocytemia."3.71Spinal meningioma during hydroxyurea therapy. A paradoxycal case report. ( Giordano, F; Pagni, CA; Savarino, A, 2002)
"In polycythemia vera (PV), treatment with chlorambucil and radioactive phosphorus (p32) increases the risk of leukemic transformation from 1% to 13-14%."3.69Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. ( Fisher, SG; Godwin, J; Nand, S; Stock, W, 1996)
" In the past 5 years from May 1986, 14 operations were conducted in our clinic on 13 patients, consisting of 4 with von Willebrand disease (vWd), 1 with hemophilia B, 4 who had warfarin administration, 3 with essential thrombocythemia and 2 with spherocytosis."3.68[Clinical experience of urological surgery of the patients with hemostatic disorder or hemolytic disease]. ( Kinoshita, S; Matsubuchi, T; Matsumiya, K; Nishimura, K; Oka, T; Takaha, M; Tsujimura, A; Yasui, M; Yasunaga, Y, 1992)
"Thrombotic events and disease progression were infrequent in both arms, whereas grade 3/4 adverse events were more frequent with PEG (46% vs 28%)."3.11A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia. ( Arango Ossa, JE; Arcasoy, MO; Bacigalupo, A; Barbui, T; Berenzon, D; Catchatourian, R; De Stefano, V; Dueck, AC; Ewing, J; Farnoud, N; Goldberg, JD; Harrison, CN; Hoffman, R; Kessler, CM; Kiladjian, JJ; Kosiorek, HE; Kremyanskaya, M; Leibowitz, DS; Levine, MF; Marchioli, R; Mascarenhas, J; McGovern, E; McMullin, MF; Mead, AJ; Mesa, RA; Nagler, A; Najfeld, V; O'Connell, CL; Penson, AV; Prchal, JT; Price, L; Rambaldi, A; Rampal, RK; Rondelli, D; Salama, ME; Sandy, L; Silver, RT; Tognoni, G; Tripodi, J; Vannucchi, AM; Weinberg, RS; Winton, EF; Yacoub, A, 2022)
" There were no significant differences in adverse events between treatment groups, and no reports of malignant transformation."3.01Cardiovascular Safety of Anagrelide Hydrochloride versus Hydroxyurea in Essential Thrombocythaemia. ( Achenbach, H; Egyed, M; Gercheva, L; Gotic, M; Kvasnicka, HM; Warzocha, K; Wu, J, 2021)
"SIRs for acute myelogenous leukemia (AML) were high in ET patients."2.87Leukemic transformation and second cancers in 3649 patients with high-risk essential thrombocythemia in the EXELS study. ( Achenbach, H; Besses, C; Birgegård, G; Folkvaljon, F; Garmo, H; Griesshammer, M; Gugliotta, L; Harrison, CN; Holmberg, L; Kiladjian, JJ; Wu, J, 2018)
" Frequency of anagrelide related adverse events was 65."2.80[Efficacy and safety of anagrelide in treatment of essential thrombocythemia: multicenter, randomized controlled clinical trial]. ( Cao, X; Fu, J; Gao, D; Ge, X; Hou, M; Jiang, B; Jin, J; Li, J; Li, K; Qian, W; Su, L; Sun, A; Wang, S; Wang, Z; Xiao, Z; Yang, L; Yang, R; Zhang, W; Zhang, X; Zhao, Y, 2015)
"Hydroxyurea (HU) was started at diagnosis in 32 "symptomatic" patients and in 33 patients aged >70 years."2.74Decisional flow with a scoring system to start platelet-lowering treatment in patients with essential thrombocythemia: long-term results. ( Alimena, G; Biondo, F; Breccia, M; Carmosino, I; Fama, A; Latagliata, R; Mazzucconi, MG; Napoleone, L; Petti, MC; Rago, A; Santoro, C; Spadea, A; Stefanizzi, C; Volpicelli, P; Vozella, F, 2009)
"Essential thrombocythemia is associated with an increased risk of thromboembolic complications."2.74The influence of low-dose aspirin and hydroxyurea on platelet-leukocyte interactions in patients with essential thrombocythemia. ( Chojnowski, K; Robak, T; Smolewski, P; Treliński, J; Tybura, M, 2009)
"Secondary thrombocytosis is a frequent secondary finding in childhood infection and inflammation."2.72Thrombocytosis in children and adolescents-classification, diagnostic approach, and clinical management. ( Cario, H; Duffert, CM; Knöfler, R; Kulozik, AE; Stockklausner, C; Streif, W, 2021)
"The priapism was managed with repeated aspiration and instillation of phenylephrine."2.66Essential Thrombocythemia Presenting with Recurrent Priapism: A Case Report and Review of Literature. ( Jain, M; Kumar, N; Tripathi, AK; Verma, SP, 2020)
"Polycythemia vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms, respectively characterized by erythrocytosis and thrombocytosis."2.52Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management. ( Barbui, T; Tefferi, A, 2015)
"Essential thrombocythemia is a chronic myeloproliferative neoplasm characterized by sustained thrombocytosis, bone marrow megakaryocytic hyperplasia and an increased risk of thrombosis and hemorrhage."2.49[Treatment of essential thrombocythemia]. ( Alvarez-Larrán, A; Besses, C; Cervantes, F, 2013)
"Treatment with busulfan or interferon-α is usually effective in hydroxyurea failures."2.48Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management. ( Tefferi, A, 2012)
"Primary thrombocythemia is a rare acquired chronic disorder of the bone marrow which can occur at any age."2.43[Primary thrombocythemia: diagnosis and therapy]. ( Petrides, PE, 2006)
" Anagrelide offers the advantage of oral dosing and long-term effectiveness at managing platelet counts."2.42Indications for lowering platelet numbers in essential thrombocythemia. ( Barbui, T, 2003)
"Hydroxyurea (HU) has a limited, if any, leukemogenic potential and should be considered the current cytotoxic drug for patients at high risk for thrombotic complications, ie, those with age above 60 years or previous thrombotic events."2.42The leukemia controversy in myeloproliferative disorders: is it a natural progression of disease, a secondary sequela of therapy, or a combination of both? ( Barbui, T, 2004)
"Major bleeding is rare and seems to be related to higher platelet counts."2.42Treatment indications and choice of a platelet-lowering agent in essential thrombocythemia. ( Barbui, T; Finazzi, G, 2003)
"The association of chronic lymphocytic leukemia (CLL) with essential thrombocythemia (ET) is an extremely rare event and until now 3 patients with such coexistence have been reported in the literature."2.42Coexistence of chronic lymphocytic leukemia and essential thrombocythemia. ( Bartkowiak, J; Góra-Tybor, J; Kordek, R; Korycka, A; Polliack, A; Robak, T; Urbańska-Ryś, H; Wawrzyniak, E, 2003)
"Its use in the treatment of essential thrombocythemia began later in 1950."2.41Treatment of the myeloproliferative disorders with 32P. ( Berlin, NI, 2000)
"Venous thrombosis is more frequent in PV than in ET; superficial or deep venous thromboses are seen."2.41[What vascular events suggest a myeloproliferative disorder?]. ( Caulier-Leleu, MT; Hachulla, E; Pasturel-Michon, U; Rose, C; Trillot, N, 2000)
"Essential thrombocythemia is a chronic myeloproliferative disease characterized by persistent thrombocytosis and an increased risk of thromboembolic complications."2.40[A management program for primary thrombocytopenia]. ( Bruserud, O; Knutsen, H, 1999)
"Aspirin (ASS) was the most frequently used drug in 47 of 93 recorded cases (51%)."2.39Essential thrombocythemia and pregnancy. ( Griesshammer, M; Heimpel, H; Pearson, TC, 1996)
"The risk of major thrombosis is higher in ET patients aged more than 60 ys."2.39Treatment strategies in essential thrombocythemia. A critical appraisal of various experiences in different centers. ( Barbui, T; Brière, J; Dupuy, E; Finazzi, G; Kiladjian, JJ, 1996)
"By contrast, in thrombocythemia, whether primary or associated with other myeloproliferative lesions, significant thrombohemorrhagic events occur."2.38The clinical spectrum of thrombocytosis and thrombocythemia. ( Frenkel, EP, 1991)
"Hydroxyurea (HU) is a guideline-recommended cytoreductive therapy for patients at high risk for MPNs."1.91Second malignancies among older patients with classical myeloproliferative neoplasms treated with hydroxyurea. ( Gore, SD; Huntington, SF; Ma, X; Podoltsev, NA; Shallis, RM; Stempel, JM; Wang, R; Zeidan, AM, 2023)
"Within the 1258 SMF of the MYSEC (MYelofibrosis SECondary to PV and ET) dataset, 135 (10."1.72Prediction of thrombosis in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study on 1258 patients. ( Albano, F; Arcaini, L; Auteri, G; Barbui, T; Benevolo, G; Bertù, L; Brociner, M; Caramazza, D; Caramella, M; Casetti, IC; Cattaneo, D; Cervantes, F; De Stefano, V; Della Porta, MG; Devos, T; Gotlib, J; Guglielmelli, P; Iurlo, A; Kiladjian, JJ; Komrokji, RS; Kuykendall, A; Maffioli, M; Merli, M; Mora, B; Palandri, F; Passamonti, F; Ross, DM; Rotunno, G; Ruggeri, M; Rumi, E; Salmoiraghi, S; Silver, RT; Vannucchi, AM, 2022)
" The incidence of all adverse events(AEs)was higher in the ANA monotherapy(45."1.51Clinical Evaluation of the Efficacy and Safety of Anagrelide Used with or without Hydroxycarbamide in Japanese Patients with Essential Thrombocythemia-A Retrospective Single-Center Study of 35 Cases. ( Fukuda, Y; Hamano, Y; Iizuka, H; Inano, T; Izumi, H; Nakamura, N; Noguchi, M; Okubo, M; Sakajiri, S; Sawada, T; Sekiguchi, Y; Sugimoto, K; Takizawa, H; Tomita, S; Wakabayashi, M, 2019)
"Cases (n = 647) were patients with second cancer (SC: carcinoma, non-melanoma skin cancer, hematological second cancer, and melanoma) and controls (n = 1234) were patients without SC, matched with cases for sex, age at MPN diagnosis, date of MPN diagnosis, and MPN disease duration."1.51Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study. ( Alvarez-Larran, A; Angona, A; Barbui, T; Beggiato, E; Benevolo, G; Bertolotti, L; Betti, S; Bonifacio, M; Cacciola, R; Carli, G; Carobbio, A; Casetti, IC; Cattaneo, D; De Stefano, V; Delaini, F; Di Veroli, A; Elli, EM; Erez, D; Finazzi, G; Fox, ML; Ghirardi, A; Gomez, M; Griesshammer, M; Guglielmelli, P; Iurlo, A; Lunghi, F; Marchetti, M; Masciulli, A; McMullin, MF; Palandri, F; Palova, M; Patriarca, A; Perez-Encinas, M; Recasens, V; Rumi, E; Scaffidi, L; Stephenson, C; Tieghi, A; Vannucchi, AM; Vianelli, N; Wille, K, 2019)
"Risk of thrombosis is higher in JAK2-mutated ET."1.51Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management. ( Barbui, T; Tefferi, A, 2019)
"Cardiovascular side effects such as ventricular tachycardia and cardiomyopathy are rare but potentially fatal and should be made known to patients before starting the medication."1.48Ventricular tachyarrhythmia in a 78-year-old woman with essential thrombocythaemia. ( Greenspan, A; Lu, M; Rodriguez-Ziccardi, M; Rubio, M, 2018)
"Hydroxyurea was the most commonly used cytoreductive therapy."1.46Multicenter Retrospective Analysis of Turkish Patients with Chronic Myeloproliferative Neoplasms. ( Bilgir, O; Çağlıyan, G; Çekdemir, D; Cömert, M; Haznedaroğlu, İC; İlhan, O; Kaya, E; Özdemirkıran, F; Şahin, F; Saydam, G; Soyer, N; Ünal, A; Vural, F; Yılmaz, M, 2017)
"Polycythemia Vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms respectively characterized by erythrocytosis and thrombocytosis; other disease features include leukocytosis, splenomegaly, thrombosis, bleeding, microcirculatory symptoms, pruritus, and risk of leukemic or fibrotic transformation."1.46Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management. ( Barbui, T; Tefferi, A, 2017)
"Essential thrombocythemia is a Philadelphia chromosome-negative chronic myeloproliferative neoplasia with a risk of bleeding and thromboembolic complications during the course of illness."1.43[Treatment outcome of patients with essential thrombocythemia at our department in Hungary]. ( Iványi, JL; Marton, É; Plander, M; Szendrei, T, 2016)
"Chronic inflammation is suggested to contribute to the Philadelphia-chromosome-negative myeloproliferative neoplasm (MPN) disease initiation and progression, as well as the development of premature atherosclerosis and may drive the development of other cancers in MPNs, both nonhematologic and hematologic."1.40Perspectives on the impact of JAK-inhibitor therapy upon inflammation-mediated comorbidities in myelofibrosis and related neoplasms. ( Hasselbalch, HC, 2014)
"At present, the treatment of polycythemia vera (PV) and essential thrombocythemia (ET) is still largely supportive and symptomatic."1.39Homoharringtonine is an effective therapy for patients with polycythemia vera or essential thrombocythemia who have failed or were intolerant to hydroxycarbamide or interferon-α therapy. ( Ding, B; Li, Y; Zhu, J, 2013)
"Previous thrombosis is an established risk factor for rethrombosis in patients with ET."1.38Cerebral infarct in a patient with a history of systemic arterial and venous thrombosis from essential thrombocythemia. ( Cho, KH; Kim, KT; Sohn, SI, 2012)
"Essential thrombocythemia is characterized by persistent elevation and functional disturbances of platelets."1.37Direct evidence for normalization of platelet function resulting from platelet count reduction in essential thrombocythemia. ( Chondropoulos, S; Dervenoulas, J; Kapsimali, V; Kopterides, P; Mantzios, G; Nikolopoulos, GK; Tsantes, AE; Tsirigotis, P; Zoi, K; Zomas, A, 2011)
"Twenty-one polycythemia vera, 28 essential thrombocythemia, eight secondary erythrocytosis, and 30 controls were studied."1.37Differential expression of JAK2 and Src kinase genes in response to hydroxyurea treatment in polycythemia vera and essential thrombocythemia. ( Albizua, E; Ayala, R; Barrio, S; Besses, C; Espinet, B; Florensa, L; Gallardo, M; Jimenez, A; Martinez-Lopez, J; Puigdecanet, E; Rapado, I; Rueda, D; Sanchez-Espiridion, B, 2011)
"Essential thrombocythemia is a rare myleoproliferative disorder in pediatrics."1.35Essential thrombocythemia in a child with elevated thrombopoietin concentrations and skeletal anomalies. ( Niazi, M; Robins, EB, 2008)
" All other treatments were continued with some dosage adjustments."1.35Management of refractory essential thrombocythemia with anagrelide in a patient undergoing hemodialysis. ( Demulder, AC; Malarme, M; Mesquita, Mdo C; Noubouossie, D; Sol, EB, 2009)
"Hydroxyurea can cause reversible inhibition of spermatogenesis and result in primary infertility."1.34Hydroxyurea therapy: a rare cause of reversible azoospermia. ( Barua, JM; Hafeez, A; Hughes, A; Masood, J, 2007)
"Treatment with hydroxyurea was started in 1997, which stabilized the platelet count."1.33[Essential thrombocythemia associated with incomplete type intestinal Behçet disease during hydroxyurea treatment]. ( Fujimi, A; Iyama, S; Kato, J; Kikuchi, S; Kobune, M; Kuribayashi, K; Matsunaga, T; Murase, K; Niitsu, Y; Okamoto, T; Satoh, T; Takimoto, R; Ueno, A, 2005)
"Hydroxyurea is a hydroxylated derivate of urea commonly used in the treatment of various hematologic disorders."1.33Leg ulcer in a patient associated with hydroxyurea therapy. ( Dissemond, J; Franckson, T; Goos, M; Hoeft, D; Knab, J; Kroger, K, 2006)
"Acute leukemia is an uncommon complication of patients with essential thrombocythemia (ET)."1.33Acute biphenotypic leukemia arising in a patient with essential thrombocythemia. ( Lee, LH; Wong, GC, 2006)
"Granulocytic sarcoma is very rare in essential thrombocythemia, and this patient may be the first reported case of essential thrombocythemia that developed multiple lesions and a pathologic fracture without transformation to overt leukemia."1.33Multiple granulocytic sarcomas in essential thrombocythemia. ( Fujita, H; Kurata, M; Maeda, A; Matsushita, A; Mori, M; Nagai, K; Nagai, Y; Takahashi, T; Tanaka, K; Tanaka, Y; Togami, K, 2006)
" Because of insufficient response to treatment after 3 weeks, the dosage of hydroxyurea was increased in both dogs to 2000 mg/m2 p."1.32Essential thrombocythaemia in two dogs. ( Favier, RP; Teske, E; van Leeuwen, M, 2004)
"Hydroxyurea (HU) has been used in patients with essential thrombocythemia (ET) to reduce the frequency and severity of thrombotic complications of the disease."1.32Hydroxyurea-induced hemolytic anemia in a patient with essential thrombocythemia. ( Jabr, FI; Shamseddine, A; Taher, A, 2004)
"Hydroxyurea and myelosan were mostly used as cytostatic drugs while erythrocyte mass transfusions and hemoexfusions (phlebotomy)--for life-support."1.32[Choice of therapy and overall survival in patients with chronic myeloproliferative diseases]. ( Pop, VP; Rukavitsyn, OA; Seriakov, AP, 2004)
" The dosage of HU was decreased to 500 mg daily when the platelet counts were found to be within normal levels."1.31Leg ulcers and hydroxyurea: report of three cases with essential thrombocythemia. ( Adigüzel, C; Cömert, A; Demirçay, Z, 2002)
"Only one report of recurrence of myocardial infarction has been previously described."1.31Essential thrombocythemia and recurrent myocardial infarction. ( Akarsu, E; Bozkurt, E; Gündogdu, M; Kaya, H; Tekin, SB, 2000)
"Management of ET in pregnancy is still very much individualized."1.31Four pregnancies in two patients with essential thrombocythaemia--a case report. ( Devendra, K; Koh, LP; Tien, SL, 2002)
"The patient who had trisomy 8 at the time of diagnosis underwent myeloid blastic transformation in 35 months."1.31Leukemic transformation with trisomy 8 in essential thrombocythemia: a report of four cases. ( Hirose, Y; Masaki, Y; Sugai, S, 2002)
"Acute myeloid leukemia was finally diagnosed in October 1998, and chromosomal analysis disclosed inv(3) in addition to -5 and -7."1.31[Essential thrombocythemia in transformation from myelodysplastic syndrome to acute myeloid leukemia with inv(3) after treatment for gastric cancer]. ( Aoki, K; Chiba, S; Hirai, H; Honda, H; Horikoshi, M; Itikawa, M; Kurokawa, M; Machida, U; Masuda, S; Mitani, K; Ogawa, S; Seo, S; Sunaga, S; Yazaki, Y, 2000)
"Hydroxyurea is a drug widely used to control myeloproliferative disorders, due in part to its relative lack of severe side effects."1.30Hydroxyurea-induced acute interstitial pneumonitis in a patient with essential thrombocythemia. ( Bello, JL; Bendaña, A; Gonzalez, S; Pérez-Encinas, M; Quintás-Cardama, A, 1999)
"Hydroxyurea was given to patients with ET with a positive history for major vascular complications or with an extreme thrombocytosis."1.30Acute coronary disease in essential thrombocythemia and polycythemia vera. ( Girolami, A; Randi, ML; Rinaldi, V; Rossi, C; Zerbinati, P, 1998)
"Drug-induced fever is a frequent (3-5% of all adverse effects) but under recognized adverse effect of several drugs."1.30[Drug-induced fever caused by hydroxyurea. Apropos of 3 new cases]. ( Allochon, Y; Blanc, M; Evreux, JC; Gallant, C; Monier, JM; Vial, T, 1998)
"A 59-year-old man had central retinal vein occlusion in the left eye as the initial sign of essential thrombocythemia."1.29Essential thrombocythemia and central retinal vein occlusion with neovascular glaucoma. ( Townsend-Pico, W; Yoshizumi, MO, 1996)
" Treatment consisted mostly of alpha-interferon (IFN-alpha 2b) subcutaneously in dosage ranging from 3 to 5 MU/m2 and hydroxyurea (HU) in conventional dosage."1.28Essential thrombocythemia--clinical features, therapy and follow-up of 12 cases. ( Gandra, M; Granato, C; Lopes, E; Principe, F; Ribeiro, MM; Silva, MJ, 1992)

Research

Studies (305)

TimeframeStudies, this research(%)All Research%
pre-19901 (0.33)18.7374
1990's44 (14.43)18.2507
2000's119 (39.02)29.6817
2010's108 (35.41)24.3611
2020's33 (10.82)2.80

Authors

AuthorsStudies
Rubin, A1
Haroon, A1
Rao, BK1
Firoz, BF1
Mazza, GL1
Mead-Harvey, C1
Mascarenhas, J4
Yacoub, A3
Kosiorek, HE2
Hoffman, R4
Dueck, AC4
Mesa, RA4
Prchal, JT4
Rambaldi, A6
Berenzon, D2
Harrison, CN8
McMullin, MF6
Vannucchi, AM9
Ewing, J2
O'Connell, CL1
Kiladjian, JJ10
Mead, AJ3
Winton, EF1
Leibowitz, DS1
De Stefano, V3
Arcasoy, MO2
Kessler, CM1
Catchatourian, R2
Rondelli, D2
Silver, RT3
Bacigalupo, A1
Nagler, A1
Kremyanskaya, M2
Levine, MF1
Arango Ossa, JE1
McGovern, E1
Sandy, L2
Salama, ME2
Najfeld, V2
Tripodi, J2
Farnoud, N2
Penson, AV1
Weinberg, RS1
Price, L1
Goldberg, JD2
Barbui, T24
Marchioli, R1
Tognoni, G1
Rampal, RK1
Gerds, AT1
Lyons, RM1
Colucci, P1
Kalafut, P1
Paranagama, D2
Verstovsek, S5
Laktib, N1
Mahtat, EM1
Lahlafi, Z1
Mouine, N1
Asfalou, I1
Aghoutane, N1
Chaib, A1
Lakhal, Z1
Doghmi, K1
Benyass, A1
Edahiro, Y2
Nicol, C1
Ajzenberg, N1
Lacut, K1
Couturaud, F1
Lippert, E1
Pan-Petesch, B1
Ianotto, JC2
Pedersen, OB1
Grove, EL1
Pasalic, L1
Ommen, HB1
Kristensen, SD1
Hvas, AM1
Chiaranairungrot, K1
Kaewpreechawat, K1
Sajai, C1
Pagowong, N1
Sukarat, N1
Piriyakhuntorn, P1
Rattanathammethee, T1
Hantrakool, S1
Chai-Adisaksopha, C2
Tantiworawit, A1
Norasetthada, L1
Rattarittamrong, E1
Wang, R2
Shallis, RM1
Stempel, JM1
Huntington, SF2
Zeidan, AM3
Gore, SD2
Ma, X2
Podoltsev, NA2
Komatsu, N3
Gill, H1
Jin, J2
Lee, SE1
Hou, HA1
Sato, T1
Qin, A1
Urbanski, R1
Shih, W1
Zagrijtschuk, O1
Zimmerman, C1
Yu, J1
Hanna, B1
Tang, J1
Chojecki, A1
Mora, B1
Guglielmelli, P4
Kuykendall, A1
Rumi, E3
Maffioli, M1
Palandri, F2
Caramella, M1
Salmoiraghi, S1
Gotlib, J2
Iurlo, A3
Cervantes, F5
Ruggeri, M4
Albano, F1
Benevolo, G2
Ross, DM1
Della Porta, MG1
Devos, T1
Rotunno, G2
Komrokji, RS1
Casetti, IC2
Merli, M1
Brociner, M1
Caramazza, D2
Auteri, G1
Cattaneo, D3
Bertù, L1
Arcaini, L1
Passamonti, F5
Park, YH1
Lee, S1
Mun, YC1
Park, DJ1
Chen, J1
Dong, H3
Fu, R3
Liu, X2
Xue, F2
Liu, W3
Chen, Y2
Sun, T2
Ju, M2
Dai, X2
Li, H1
Wang, W1
Chi, Y1
Yang, R4
Zhang, L5
Zhang, D1
Zhou, H1
Zhang, X2
Huang, Y1
Khodier, M1
Gadó, K1
Kosiorek, H1
Baer, MR1
Ritchie, E1
Kessler, C1
Winton, E1
Finazzi, MC1
Leibowitz, D1
Vadakara, J1
Rosti, V1
Hexner, E1
Papaemmanuil, E1
Salama, M1
Singer-Weinberg, R1
Rampal, R1
Mesa, R2
O'Sullivan, JM1
Hamblin, A2
Yap, C2
Fox, S2
Boucher, R1
Panchal, A2
Alimam, S2
Dreau, H1
Howard, K1
Ware, P1
Cross, NCP2
Valentine, RM1
Barkhuizen, A1
Roberts, R1
Ford, C1
Gama, R1
Bolaman, AZ1
Yavaşoǧlu, İ2
Kellner, A1
Dombi, P2
Illes, A2
Demeter, J2
Homor, L2
Ercsei, I1
Simon, Z2
Karadi, E2
Herczeg, J1
Gy Korom, V1
Gasztonyi, Z1
Szerafin, L1
Udvardy, M3
Egyed, M3
Verma, SP1
Kumar, N1
Jain, M1
Tripathi, AK1
Ielasi, A1
Loffi, M1
Buono, A1
De Blasio, G1
Tespili, M1
Alvarez-Larrán, A8
Angona, A5
Andrade-Campos, M1
Soledad Noya, M1
Teresa Gómez-Casares, M1
Cuevas, B1
Caballero, G1
García-Hernández, C1
García-Gutiérrez, V1
Palomino, A1
Ferrer-Marín, F3
Isabel Mata-Vázquez, M1
Moretó, A1
Magro, E1
Murillo, I1
Manuel Alonso-Domínguez, J1
María Guerra, J1
Guerrero, L1
María Raya, J1
Pérez-Encinas, M3
Carreño-Tarragona, G1
Fox, L1
Pastor-Galán, I1
Bellosillo, B5
Hernández-Boluda, JC5
Bewersdorf, JP1
Gotic, M2
Gercheva, L1
Warzocha, K1
Kvasnicka, HM3
Achenbach, H2
Wu, J2
Suzuki, M1
Maezima, E1
Ohnuma, T1
Kawamura, T1
Kirito, K1
Okada, Y2
Kimura, F1
Kwiatkowski, J1
Kuliszkiewicz-Janus, M1
Rymer, W1
Jaźwiec, B1
Małecki, R1
Stockklausner, C1
Duffert, CM1
Cario, H1
Knöfler, R1
Streif, W1
Kulozik, AE1
Loscocco, GG1
Antonioli, E3
Romano, I1
Vergoni, F1
Mannelli, F1
Krečak, I1
Lucijanić, M1
Choi, HS1
Hong, J1
Hwang, SM1
Lee, JH1
Ma, Y1
Kim, SA1
Lee, JY1
Lee, JO3
Bang, SM3
Huang, X1
Ma, T1
Zhu, Y1
Jiao, B1
Yu, S1
Wang, K1
Mi, JQ1
Ren, R1
Dam, MJB1
Pedersen, RK1
Knudsen, TA1
Andersen, M1
Skov, V1
Kjaer, L1
Hasselbalch, HC4
Ottesen, JT1
Na, J1
Choi, SY1
Baek, S1
Lee, H1
Santoro, C2
Sperduti, I1
Latagliata, R3
Baldacci, E1
Anaclerico, B2
Avvisati, G1
Breccia, M3
Buccisano, F1
Cedrone, M1
Cimino, G1
De Gregoris, C1
De Muro, M1
Di Veroli, A3
Leonetti Crescenzi, S1
Montanaro, M2
Montefusco, E1
Porrini, R1
Rago, A2
Spadea, A2
Spirito, F1
Villivà, N2
Andriani, A2
Alimena, G2
Mazzucconi, MG3
Barosi, G5
Gattoni, E1
Pieri, L2
Zhen, H1
Granier, M1
Assad, A1
Cazzola, M3
Kantarjian, HM1
Platto, J1
Alexander, CE1
Kurtzman, DJB1
Özpolat, T1
Kayar, Y1
Sahutoglu, T1
Gbandi, E1
Houlton, A1
Wood, M1
Chen, F1
Coppell, J1
Panoskaltsis, N1
Knapper, S1
Ali, S1
Scherber, R1
Rodriguez-Ziccardi, M1
Rubio, M1
Lu, M1
Greenspan, A1
Tashi, T1
Swierczek, S1
Kim, SJ1
Song, J1
Heikal, N1
King, KY2
Hickman, K1
Litton, S1
Renso, R1
Aroldi, A2
Pioltelli, P2
Gambacorti-Passerini, C1
Elli, EM2
Godfrey, AL1
Campbell, PJ5
MacLean, C1
Buck, G3
Cook, J1
Temple, J1
Wilkins, BS3
Wheatley, K3
Nangalia, J1
Grinfeld, J1
Forsyth, C1
Green, AR7
Tefferi, A17
Birgegård, G6
Folkvaljon, F1
Garmo, H1
Holmberg, L1
Besses, C12
Griesshammer, M9
Gugliotta, L6
Marcellino, B1
Sankar, K1
Stein, BL2
Melikyan, AL1
Subortseva, IN1
Gilyazitdinova, EA1
Koloshejnova, TI1
Pustovaya, EI1
Egorova, EK1
Kovrigina, AM1
Sudarikov, AB1
Abdullaev, AO1
Lomaia, EG1
Siordiya, NT1
Zaritskey, AY1
Savchenko, VG1
Zhu, M1
Wang, X1
Davidoff, AJ1
Giri, S1
Randi, ML9
Bertozzi, I1
Putti, MC1
Pan, T1
Liu, XF1
Huang, YT1
Fu, RF1
Gu, WJ1
Gao, YC1
Yang, RC1
Elli, E2
Trapè, G1
Fianchi, L1
Niscola, P1
Centra, A1
Montanaro, G1
Martini, V1
Carmosino, I2
Voso, MT1
Foà, R1
Ghirardi, A1
Masciulli, A1
Carobbio, A3
Vianelli, N1
Betti, S1
Delaini, F3
Bonifacio, M1
Scaffidi, L1
Patriarca, A1
Stephenson, C1
Palova, M1
Bertolotti, L1
Erez, D1
Gomez, M4
Wille, K1
Lunghi, F2
Fox, ML1
Beggiato, E1
Carli, G1
Cacciola, R1
Tieghi, A1
Recasens, V1
Marchetti, M4
Finazzi, G12
Sekiguchi, Y1
Wakabayashi, M1
Takizawa, H1
Iizuka, H1
Sakajiri, S1
Sugimoto, K1
Inano, T1
Fukuda, Y1
Hamano, Y1
Tomita, S1
Izumi, H1
Okubo, M1
Nakamura, N1
Sawada, T1
Noguchi, M2
Bain, BJ1
Garnett, C1
Deplano, S1
Naresh, K1
Kanfer, E1
Martínez-Avilés, L4
Camacho, L1
Pairet, S1
Fernández-Rodriguez, MC1
Ancochea, A2
Haznedaroglu, IC2
Nunoi, H1
Hirooka, M1
Ochi, H1
Koizumi, Y1
Tokumoto, Y1
Abe, M1
Tada, F1
Ikeda, Y2
Matsuura, B1
Tanaka, H1
Tsuda, T1
Mochizuki, T1
Hiasa, Y1
Onji, M1
Litt, E1
Thomas, B1
Smyth, J1
Desoysa, L1
Watson, D1
Nishihori, T1
Hassoun, Y1
Shain, K1
Alsina, M1
Kharfan-Dabaja, MA1
Grisouard, J1
Ojeda-Uribe, M1
Looser, R1
Hao-Shen, H1
Lundberg, P1
Duek, A1
Jeandidier, E1
Karow, A1
Skoda, RC1
Ling, C1
Zhu, GH1
Jin, L1
Ahn, IE1
Natelson, E1
Rice, L1
Singh, A1
Chaudhary, R1
Nityanand, S1
Harrison, C5
Coll, R2
Smith, J2
Abhyankar, B1
Sever, M1
Newberry, KJ1
Zhang, ZR1
Duan, YC1
Antelo, ML2
Burgaleta, C3
Mata, MI1
Xicoy, B1
Martínez-Trillos, A1
Gómez-Casares, MT1
Durán, MA1
Marcote, B1
Senín, A1
Vicente, V2
Huang, BT1
Zeng, QC1
Zhao, WH1
Li, BS1
Chen, RL1
Riley, CH2
Hansen, M1
Brimnes, MK2
Bjerrum, OW2
Straten, PT2
Svane, IM2
Jensen, MK2
Michiels, JJ4
Pich, A1
De Raeve, H1
Gadisseur, A1
Björkholm, M1
Hultcrantz, M1
Derolf, ÅR1
Yoshimoto, G1
Miyamoto, T1
Shirane, S1
Araki, M1
Morishita, S1
Sunami, Y1
Hironaka, Y1
Koike, M1
Sato, E1
Ohsaka, A1
Double, G1
Lim, Y2
Kim, SH1
Kim, JW1
Kim, YJ1
Lee, KW1
Lee, JS1
Lizarralde Palacios, E1
Gutiérrez Macías, A1
Rámiz Martínez, M1
Escalante Boleas, M1
Arcasoy, M1
Nguyen, MH1
Shah, N1
Moliterno, A1
Jamieson, C1
Pollyea, DA1
Scott, B1
Wadleigh, M1
Levine, R1
Komrokji, R1
Klisovic, R1
Gundabolu, K1
Kropf, P1
Wetzler, M1
Oh, ST1
Ribeiro, R1
Paschal, R1
Mohan, S1
Podoltsev, N1
Prchal, J1
Talpaz, M1
Snyder, D1
Lancellotti, S1
Dragani, A1
Ranalli, P1
Petrucci, G1
Basso, M1
Tartaglione, R1
Rocca, B2
De Cristofaro, R1
Samuelson, B1
Garcia, D1
Watanabe, N1
Yasuda, H1
Aota, Y1
Ando, J1
Aoyama, T1
Tanaka, M1
Gotoh, A1
Matatall, KA1
Shen, CC1
Goodell, MA1
Swierczek, SI1
Worley, B1
Glassman, SJ1
Ge, X1
Yang, L1
Qian, W1
Li, J1
Cao, X1
Jiang, B1
Wang, Z1
Hou, M1
Zhang, W1
Xiao, Z1
Zhao, Y1
Gao, D1
Wang, S1
Sun, A1
Fu, J1
Su, L1
Li, K1
Cozzani, E1
Merlo, G1
Burlando, M1
Pierri, I1
Parodi, A1
Verger, E1
Cassinat, B2
Chauveau, A1
Dosquet, C1
Giraudier, S2
Schlageter, MH1
Yassin, MA1
Al-Dewik, N1
Carillo, S2
Legouffe, E1
Ugo, V1
Chomienne, C3
Treliński, J4
Okońska, M1
Robak, M1
Chojnowski, K4
Iványi, JL1
Marton, É1
Plander, M1
Szendrei, T1
Pérez Encinas, M1
Raya, JM1
Hernández-Rivas, JM1
Jiménez Velasco, A1
Martínez Lopez, J1
Soyer, N1
Cömert, M1
Çekdemir, D1
Yılmaz, M1
Ünal, A1
Çağlıyan, G1
Bilgir, O1
İlhan, O1
Özdemirkıran, F1
Kaya, E1
Şahin, F1
Vural, F1
Saydam, G1
Shimazu, Y1
Fujimura, K1
Sivakumaran, Y1
Freeman, A1
Inoue, S1
Okiyama, N1
Okune, M1
Shiraki, N1
Kessoku, R1
Fujimoto, M1
Piccin, A1
Steurer, M1
Feistritzer, C1
Murphy, C1
Eakins, E1
Van Schilfgaarde, M1
Corvetta, D1
Di Pierro, AM1
Pusceddu, I1
Marcheselli, L1
Gambato, R1
Langes, M1
Veneri, D1
Perbellini, O1
Pacquola, E1
Gottardi, M1
Gherlinzoni, F1
Mega, A1
Tauber, M1
Mazzoleni, G1
Piva, E1
Plebani, M1
Krampera, M1
Gastl, G1
Ahmed, AK1
Youssef, A1
Skeik, N1
Ricksten, A2
Palmqvist, L1
Johansson, P3
Andreasson, B4
Edlich, RF1
Long, WB1
Cochran, AA1
Kelley, AR1
Woode, DR1
Greene, JA1
Takahashi, GW1
Gangat, N2
Girodon, F1
Schaeffer, C1
Cleyrat, C1
Mounier, M1
Lafont, I1
Santos, FD1
Duval, A1
Vidal, A1
Maynadié, M1
Hermouet, S1
Radaelli, F1
Onida, F1
Rossi, FG1
Zilioli, VR1
Colombi, M1
Usardi, P1
Calori, R1
Zanella, A1
Ruzzon, E2
Piccoli, A1
Tezza, F2
Scapin, M1
Scandellari, R2
Fabris, F7
Spanoudakis, E2
Bazdiara, I1
Kotsianidis, I2
Margaritis, D2
Goutzouvelidis, A2
Christoforidou, A2
Tsatalas, C2
Bourikas, G2
Pantelidou, D1
Anastasiadis, A1
Kaloutsi, V1
Caracciolo, C1
Barone, R1
Malato, A1
Saccullo, G1
Cigna, V1
Berretta, S1
Schinocca, L1
Quintini, G1
Abbadessa, V1
Di Raimondo, F1
Siragusa, S1
Bildirici, U1
Celikyurt, U1
Ural, E1
Bareford, D3
Erber, WN1
Wright, P1
Allegra, A1
Alonci, A1
Penna, G1
D'Angelo, A1
Rizzotti, P1
Granata, A1
Musolino, C1
Napoleone, L1
Fama, A1
Biondo, F1
Volpicelli, P1
Vozella, F1
Stefanizzi, C1
Petti, MC1
Kurosawa, H1
Okuya, M1
Matsushita, T1
Kubota, T1
Endoh, K1
Kuwashima, S1
Hagisawa, S1
Sato, Y1
Fukushima, K1
Sugita, K1
Park, MJ1
Hayashi, Y1
Arisaka, O1
Tybura, M1
Smolewski, P3
Robak, T3
Sandhu, G1
Ranade, A1
Siddiqi, S1
Balderacchi, JL1
Ranta, D1
Bonmati, C1
Martorell-Calatayud, A1
Requena, C1
Nagore-Enguídanos, E1
Guillén-Barona, C1
Kumagai, N1
Mitsutake, R1
Miura, S1
Kawamura, A1
Takamiya, Y1
Nishikawa, H1
Uehara, Y1
Saku, K1
Beer, PA1
Mesquita, Mdo C1
Sol, EB1
Malarme, M1
Noubouossie, D1
Demulder, AC1
Mizutani, S1
Kuroda, J1
Shimizu, D1
Horiike, S1
Taniwaki, M1
Rolf, N1
Suttorp, M1
Budde, U1
Siegert, G1
Knoefler, R1
Pancrazzi, A1
Ponziani, V1
Bartalucci, N1
Tozzi, L1
Bosi, A1
Dingli, D2
Cella, G1
Vianello, F1
Panova-Noeva, M2
Vignoli, A1
Russo, L2
Falanga, A2
Rodeghiero, F4
Wierzbowska, A1
Krawczyńska, A1
Sakowicz, A1
Pietrucha, T1
Weston, H1
Cowell, V1
Grimmett, K1
Saal, R1
Jones, M1
Mills, T1
Gill, D1
Marlton, P1
Bird, R1
Mollee, P1
Tsuchiya, S1
Ichioka, S1
Sekiya, N1
Selvan, SR1
Sheehy, PF1
Heinemann, FS1
Anbuganapathi, S1
Amat, P1
Navarro, B1
Teruel, A1
Martínez-Ruiz, F1
Mojal, S1
Longarón, R1
Salar, A1
Florensa, L2
Serrano, S1
Ayvaz, OC1
Kadikoylu, G1
Bozkurt, G1
Bolaman, Z1
Albizua, E1
Gallardo, M1
Barrio, S1
Rapado, I1
Jimenez, A1
Ayala, R1
Rueda, D1
Sanchez-Espiridion, B1
Puigdecanet, E1
Espinet, B1
Martinez-Lopez, J1
Zalcberg, IR1
Ayres-Silva, J1
de Azevedo, AM1
Solza, C1
Daumas, A1
Bonamino, M1
Maugeri, N1
Malato, S1
Femia, EA1
Pugliano, M1
Campana, L1
Rovere-Querini, P1
Lussana, F1
Podda, G1
Cattaneo, M1
Ciceri, F1
Manfredi, AA1
Buoro, S1
Leuzzi, A1
Ottomano, C1
Ten Cate, H1
Tsantes, AE1
Nikolopoulos, GK1
Tsirigotis, P1
Zoi, K1
Zomas, A1
Kapsimali, V1
Kopterides, P1
Chondropoulos, S1
Dervenoulas, J1
Mantzios, G1
Kluger, N1
Naud, M1
Françès, P1
Belotti, A1
Speranza, T1
Lanzi, E1
Pogliani, E1
Francis, S1
Baggott, C1
Baginott, C1
Thachil, J1
Kim, KT1
Sohn, SI1
Cho, KH1
Cebula-Obrzut, B1
Verdure, P1
Lefaucheur, R1
Guegan-Massardier, E1
Triquenot-Bagan, A1
Gerardin, E1
Maltête, D1
Frewin, R1
Dowson, A1
Naganuma, M1
Isoda, K1
Nishi, S1
Ito, K1
Hirano, T1
Li, Y1
Zhu, J1
Ding, B1
Dua, V1
Yadav, SP1
Kumar, V1
Saxena, R1
Sachdeva, A1
Reményi, G1
Szász, R1
Debreceni, IB1
Szarvas, M1
Batár, P1
Nagy, B1
Kappelmayer, J1
Gisslinger, H3
Holowiecki, J1
Penka, M1
Thiele, J2
Kralovics, R1
Petrides, PE4
Pereira, A1
Arellano-Rodrigo, E1
Kerguelen, A1
Márquez, JA1
González, N1
César, J1
Bernasconi, P1
Boni, M1
Cavigliano, PM1
Calatroni, S1
Brusamolino, E1
Volpe, G1
Pistorio, A1
Giardini, I1
Caresana, M1
Lazzarino, M1
Bernasconi, C1
Giordano, F1
Savarino, A1
Pagni, CA1
McCarthy, L1
Eichelberger, L1
Skipworth, E1
Danielson, C1
Tsimberidou, AM1
Giles, FJ1
Demirçay, Z1
Cömert, A1
Adigüzel, C1
Wahlin, A2
Golovleva, I1
Braester, A2
Sironi, M1
Bertola, G1
Lodato, A1
Spinelli, M1
Sciariada, L1
Azagury, M1
Martelli, JM1
Morcelet, M1
Duboucher, C1
Flandrin, G1
Langer, C1
Urbańska-Ryś, H1
Góra-Tybor, J1
Wawrzyniak, E1
Korycka, A1
Bartkowiak, J1
Kordek, R1
Polliack, A1
Kornblihtt, LI1
Heller, PG1
Correa, G1
Castañón, M1
Genoud, V1
Vassallu, P1
Sarano, J1
Kordich, L1
Molinas, FC1
Grossi, A2
Liberato, LN1
Tura, S2
Schafer, AI2
Candoni, A1
Tiribelli, M1
Fanin, R1
Vassiliou, GS1
Curtin, N1
Favier, RP1
van Leeuwen, M1
Teske, E1
Wasslavik, C1
Johansson, B1
Jabr, FI1
Shamseddine, A1
Taher, A1
Rukavitsyn, OA1
Pop, VP1
Seriakov, AP1
Elliott, MA1
Curtin, NJ1
East, CL1
van der Walt, JD1
Reilly, JT4
Grigg, AP2
Revell, P1
Woodcock, BE1
Costello, R1
O'Callaghan, T1
Sébahoun, G1
Asghar, R1
Behzad, E1
Mohammad, GA1
Kobune, M1
Kato, J1
Kuribayashi, K1
Iyama, S1
Fujimi, A1
Murase, K1
Ueno, A1
Kikuchi, S1
Satoh, T1
Okamoto, T1
Takimoto, R1
Matsunaga, T1
Niitsu, Y1
Dissemond, J1
Hoeft, D1
Knab, J1
Franckson, T1
Kroger, K1
Goos, M1
Elkassar, N1
Hetet, G2
Balitrand, N1
Conejero, C1
Briere, J6
Fenaux, P2
Grandchamp, B2
Cesar, JM1
Cabello, P2
Ferro, T2
Navarro, JL1
Luzzatto, G1
Schmitt-Graeff, A1
Rain, JD1
Bernard, JF1
Wong, GC1
Lee, LH1
Chang, H1
Shim, CY1
Cheong, JW1
Pyo, JY1
Ko, YG1
Choi, D1
Jang, Y1
Wolanskyj, AP1
McClure, RF1
Li, CY1
Schwager, S1
Wu, W1
Tanaka, Y1
Nagai, Y1
Mori, M1
Fujita, H1
Togami, K1
Kurata, M1
Matsushita, A1
Maeda, A1
Nagai, K1
Tanaka, K1
Takahashi, T1
Hasselbalch, H1
Lengfelder, E1
Henry, L1
Jourdan, E1
Arnaud, A1
Brun, S1
Lavabre-Bertrand, T1
Masood, J1
Hafeez, A1
Hughes, A1
Barua, JM1
Robins, EB1
Niazi, M1
Messouak, O1
Alaoui Faris, M1
Benabdejlil, M1
Tizniti, S1
Belahsen, F1
Usukine, K1
Shinhori, H1
Idetsuki, T1
Taoka, K1
Nakasone, H1
Kida, M1
Iki, S1
Urabe, M1
Oseto, K1
Igarashi, A1
McLornan, D1
McMullin, M1
Cacciola, RR1
Di Francesco, E1
Pezzella, F1
Tibullo, D1
Giustolisi, R1
Cacciola, E1
Landolfi, R1
Di Gennaro, L1
Kelly, SV1
Burke, RF1
Lee, KS1
Torloni, AS1
Lee, RW1
Northfelt, D1
Fonseca, R1
Fuse, I1
Bieniaszewska, M1
Hellmann, A1
Kabata, J1
Rasze-Ja-Specht, A1
Cinkotai, KI1
Wood, P1
Donnai, P1
Kendra, J1
van Genderen, PJ2
Meisel, S1
Shpilberg, O1
Ramot, B1
Ben-Bassat, I1
Furgerson, JL1
Vukelja, SJ1
Baker, WJ1
O'Rourke, TJ1
Najean, Y2
Berkahn, LC1
Nelson, J1
Ockelford, PA1
Browett, PJ1
Nand, S1
Stock, W1
Godwin, J1
Fisher, SG1
Yoshizumi, MO1
Townsend-Pico, W1
Iwama, H1
Kawakubo, K1
Nehashi, Y1
Kuriyama, Y1
Iwase, O1
Ohyashiki, K1
Watanabe, K1
Ebihara, Y1
Toyama, K1
Heimpel, H1
Pearson, TC1
Dupuy, E1
el-Kassar, N1
De Salvo, L1
Plumacher, Z1
Gómez, O1
Weir-Medina, J1
Paz, L1
Salas, D1
Leenknegt, H1
Brodsky, I1
Engström, KG1
Löfvenberg, E2
Carneskog, J1
Kutti, J2
Wadenvik, H1
Lundberg, PA1
Lindstedt, G1
Rossi, C3
Zerbinati, P1
Rinaldi, V1
Girolami, A6
Liebschutz, S1
Quéré, I1
Lukasik, E1
Dereure, O1
Rondes, J1
Janbon, C1
Ohto, T1
Shihara, H1
Miyauchi, Y1
Nakajima, N1
Las Heras, G1
Juncà Piera, J1
Ruiz-Argüelles, GJ1
Ruiz-Delgado, GJ1
Ruiz-Reyes, G1
Chernoff, SG1
Westerman, DA1
Schwarer, A1
Hackwell, S1
Ross, F1
Cullis, JO1
Quintás-Cardama, A1
Gonzalez, S1
Bendaña, A1
Bello, JL1
Knutsen, H1
Bruserud, O1
Silverstein, MN2
Horikoshi, M1
Machida, U1
Itikawa, M1
Seo, S1
Masuda, S1
Kurokawa, M1
Ogawa, S1
Sunaga, S1
Honda, H1
Aoki, K1
Chiba, S1
Mitani, K1
Hirai, H1
Yazaki, Y1
Menapace, L1
Berlin, NI1
Kaya, H1
Gündogdu, M1
Tekin, SB1
Akarsu, E1
Bozkurt, E1
Wan, TS1
Ma, SK1
Chan, LC1
Solberg, LA1
Swolin, B1
Tabata, M1
Imagawa, S1
Tarumoto, T1
Ohmine, K1
Hatake, K1
Miura, Y1
Ozawa, K1
Quitt, M1
Hachulla, E1
Rose, C1
Trillot, N1
Caulier-Leleu, MT1
Pasturel-Michon, U1
Jantunen, R1
Juvonen, E1
Ikkala, E1
Oksanen, K1
Anttila, P1
Ruutu, T1
Guilmin, F1
Bangerter, M1
Grünewald, M1
Wright, CA1
Gallant, C1
Vial, T1
Allochon, Y1
Monier, JM1
Blanc, M1
Evreux, JC1
Krsnik, I1
García Suárez, J1
Vázquez Mazariego, Y1
Das, R1
Kaur, U1
Garewal, G1
Koh, LP1
Devendra, K1
Tien, SL1
Hirose, Y1
Masaki, Y1
Sugai, S1
Matsumiya, K1
Nishimura, K1
Tsujimura, A1
Yasunaga, Y1
Oka, T1
Takaha, M1
Yasui, M1
Kinoshita, S1
Matsubuchi, T1
Campbell, KM1
Schubert, DS1
Lopes, E1
Ribeiro, MM1
Silva, MJ1
Gandra, M1
Principe, F1
Granato, C1
Longo, G1
Rafanelli, D1
Rossi Ferrini, P1
Pulik, M1
Teillet, F1
Frenkel, EP1
Legrand, M1
Poirier, O1
Senechal, A1
Arrago, JP1
van den Anker-Lugtenburg, PJ1
Sizoo, W1

Clinical Trials (9)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea Therapy in the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET)[NCT01259856]Phase 3168 participants (Actual)Interventional2011-09-30Completed
Mechanism of Action of Interferon in the Treatment of Myeloproliferative Neoplasms[NCT05850273]50 participants (Anticipated)Observational2023-03-16Recruiting
Prospective, Longitudinal, Non-Interventional Study of Disease Burden and Treatment of Patients With Low-Risk Myelofibrosis (MF) or High-Risk Essential Thrombocythemia (ET) or ET Patients Receiving ET-Directed Therapy[NCT02953704]1,469 participants (Actual)Observational2016-12-31Completed
A Phase 3, Open-Label, Multicenter, Randomized, Active-controlled Study to Assess PK and Compare the Efficacy, Safety, and Tolerability of P1101 vs Anagrelide as 2nd Line Therapy for Essential Thrombocythemia (SURPASS ET): The Core Study and Its Extension[NCT04285086]Phase 3174 participants (Actual)Interventional2020-08-25Active, not recruiting
A Phase IIIb, Randomized, Open Label Study to Compare the Safety, Efficacy and Tolerability of Anagrelide Hydrochloride Versus Hydroxyurea in High-Risk Essential Thrombocythaemia Patients.[NCT00202644]Phase 4150 participants (Actual)Interventional2006-01-13Completed
A Randomised Trial to Compare Aspirin vs Hydroxyurea/Aspirin in 'Intermediate Risk' Primary Thrombocythaemia and Aspirin Only With Observation in 'Low Risk'Primary Thrombocythaemia[NCT00175838]1,398 participants (Actual)Interventional1997-07-31Completed
A Non-Interventional, Post Authorisation Safety Study, to Continuously Monitor Safety and Pregnancy Outcomes in a Cohort of At-Risk Essential Thrombocythaemia (ET) Subjects Exposed to Xagrid Compared to Other Conventional Cytoreductive Treatments[NCT00567502]3,647 participants (Actual)Observational2005-05-31Completed
A Single Blind, Multi-centre, Randomised Multinational Phase III Study to Compare the Efficacy and Tolerability of Anagrelide vs Hydroxyurea in Patients With Essential Thrombocythaemia[NCT01065038]Phase 30 participants Interventional2002-09-30Completed
Molecular Changes and Biomarkers in Chronic Myeloproliferative Disorders[NCT00433862]8 participants (Actual)Observational2007-02-06Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change in the Total Symptom Score (TSS)

Change in the Total Symptom Score which assessed improvement in disease symptoms measured by the change in TSS from the Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) instrument being used in this study from baseline to 12 months. This 19 item instrument includes the previously validated 9 item brief fatigue inventory (BFI), symptoms related to splenomegaly, inactivity, cough, night sweats, pruritus, bone pains, fevers, weight loss, and an overall quality of life assessment. Each item is scored from 0-10 with full scale from 0-190, with higher scores mean worse symptoms. (NCT01259856)
Timeframe: baseline and 12 months

Interventionscore on a scale (Mean)
PEGASYS1.16
Hydroxyurea-1.0

Number of Participants With Major Cardiovascular Events After Therapy

(NCT01259856)
Timeframe: 4 years

InterventionParticipants (Count of Participants)
PEGASYS1
Hydroxyurea1

Number of Participants With Complete Remission (CR)

Number of participants with Complete Remission after 12 months of therapy assessed by hematologic response rates two strata of patients with high risk polycythemia vera (PV) or high risk essential thrombocythemia (ET). Complete remission means no evidence of disease. (NCT01259856)
Timeframe: 12 months

,
InterventionParticipants (Count of Participants)
Essential ThrombocythemiaPolycythemia Vera
Hydroxyurea1913
PEGASYS1712

Number of Participants With Grade 3 and Grade 4 Hematological and Non-hematological Events

Number of Participants with Grade 3 and Grade 4 Hematological and Non-hematological Events using the Common Terminology Criteria for Adverse Events (CTCAE) 4.0 to assess the toxicity, safety and tolerability of therapy (Pegylated Interferon Alfa-2a vs. Hydroxyurea). (NCT01259856)
Timeframe: 4 years

,
InterventionParticipants (Count of Participants)
Grade 3 Hematological eventGrade 4 Hematological eventGrade 3 Non-hematological eventGrade 4 Non-hematological event
Hydroxyurea20143
PEGASYS30272

Number of Participants With Partial Remission (PR)

Number of participants with Partial Remission after 12 months of therapy assessed by hematologic response rates two strata of patients with high risk polycythemia vera (PV) or high risk essential thrombocythemia (ET). Partial Remission means decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment. (NCT01259856)
Timeframe: 12 months

,
InterventionParticipants (Count of Participants)
Essential ThrombocythemiaPolycythemia Vera
Hydroxyurea1117
PEGASYS1025

Number of Participants With Progression of Disease or Death

"Survival and incidence of development of myelodysplastic syndrome, myelofibrosis, or leukemic transformation after therapy~To estimate survival and incidence of development of myelodysplastic syndrome, myelofibrosis, or leukemic transformation after therapy (Pegylated Interferon Alfa-2a vs. Hydroxyurea) by capturing the rate of progression to a more advanced myeloid malignancy." (NCT01259856)
Timeframe: 4 years

,
InterventionParticipants (Count of Participants)
DeathProgression to MF
Hydroxyurea10
PEGASYS00

Number of Participants With Thrombotic and Haemorrhagic Events

Thrombohaemorrhagic events are a well-known complication of the underlying essential thrombocythemia (ET) and disease progression. Events such as arterial and venous thrombosis, serious haemorrhage (including gastrointestinal haemorrhage), and death from vascular causes have been reported in participants who received cytoreductive treatment. (NCT00202644)
Timeframe: From the signing of informed consent until the last study-related visit (Month 36)

Interventionparticipants (Number)
Anagrelide30
Hydroxyurea16

Percentage of Participants With Complete Response

A complete response was defined as a platelet count of less than (<) 400x10^9/Liter which was confirmed over 2 consecutive visits at least 28 days apart. (NCT00202644)
Timeframe: Baseline up to Month 36

Interventionpercenatge of participants (Number)
Anagrelide58.9
Hydroxyurea58.8

Percentage of Participants With Partial Response

A partial response is defined as a platelet count of 400-600 x 10^9/Liter and a reduction in platelet count of at least 200 x 10^9/Liter from baseline which was confirmed over 2 consecutive visits at least 28 days apart. (NCT00202644)
Timeframe: Baseline up to Month 36

Interventionpercentage of participants (Number)
Anagrelide21.9
Hydroxyurea27.9

Platelet Count at Month 6

Platelet count was evaluated. (NCT00202644)
Timeframe: Month 6

Intervention10^9 platelets per liter (Mean)
Anagrelide418.6
Hydroxyurea396.0

Time to Complete Response

Time in days from the date of the first dose of study medication to the date of the first visit at which response was classified. If a participant did not achieve response then they were censored at their last visit in the study (Month 36 or withdrawal). (NCT00202644)
Timeframe: Baseline up to Month 36

Interventiondays (Median)
Anagrelide177.0
Hydroxyurea123.0

Time to Partial Response

Time in days from the date of the first dose of study medication to the date of the first visit at which response was classified. If a participant did not achieve response then they were censored at their last visit in the study (Month 36 or withdrawal). (NCT00202644)
Timeframe: Baseline up to Month 36

Interventiondays (Median)
Anagrelide61.0
Hydroxyurea47.0

Change From Baseline in Left Ventricular Ejection Fraction (LVEF) Over Time

The LVEF was measured by echocardiography and considered a sufficiently sensitive measure to evaluate any changes in cardiac function. (NCT00202644)
Timeframe: Baseline and Month 1, 2, 3, 6, 9, 12, 18, 24, 30 and 36

,
Interventionpercentage of ejection fraction (Mean)
BaselineChange from baseline at Month 1Change from baseline at Month 2Change from baseline at Month 3Change from baseline at Month 6Change from baseline at Month 9Change from baseline at Month 12Change from baseline at Month 18Change from baseline at Month 24Change from baseline at Month 30Change from baseline at Month 36
Anagrelide66.40.51.20.1-0.5-0.8-0.8-2.0-1.8-1.8-1.7
Hydroxyurea66.9-1.10-0.4-0.6-1.5-0.6-1.2-1.7-0.2-0.6

Change From Baseline in Platelet Counts at Month 3 and 36

Platelet count was evaluated throughout the study. (NCT00202644)
Timeframe: Baseline and Month 3 and 36

,
Intervention10^9 platelets per liter (Mean)
Change from baseline at Month 3Change from baseline at Month 36
Anagrelide575.3531.0
Hydroxyurea462.2462.8

Change From Baseline in Red Blood Cell Count Over Time

Red blood cell count was evaluated throughout the study. (NCT00202644)
Timeframe: Baseline and Month 6, 12, 18, 24, 30 and 36

,
Intervention10^12 cells per liter (Mean)
BaselineChange from baseline at Month 6Change from baseline at Month 12Change from baseline at Month 18Change from baseline at Month 24Change from baseline at Month 30Change from baseline at Month 36
Anagrelide4.757-0.227-0.246-0.225-0.299-0.295-0.366
Hydroxyurea4.787-1.467-1.398-1.323-1.281-1.339-1.362

Change From Baseline in White Blood Cell Count Over Time

White blood cell count was evaluated throughout the study. (NCT00202644)
Timeframe: Baseline and Month 6, 12, 18, 24, 30 and 36

,
Intervention10^9 cells per liter (Mean)
BaselineChange from baseline at Month 6Change from baseline at Month 12Change from baseline at Month 18Change from baseline at Month 24Change from baseline at Month 30Change from baseline at Month 36
Anagrelide9.13-0.38-1.00-1.18-1.24-1.00-1.63
Hydroxyurea10.20-5.02-4.79-4.46-4.82-4.59-4.46

Cumulative Dose for Each Essential Thrombocythemia (ET) Therapy

Since the study is observational nature, interpreting the table is difficult due to inconsistencies in reporting the units of the dose. (NCT00567502)
Timeframe: Up to 5 years

Interventionmilligram (mg) (Mean)
XAGRID Only29096.2
Other (Cytoreductives)-Hydroxyurea957751.4
Other (Cytoreductives)-Interferon Alpha3592.2
Other (Cytoreductives)-Pegylated Interferon5103.1
Other (Cytoreductives)-Busulphan7749.6
Other (Cytoreductives)-Pipobroman28612.7
Other (Cytoreductives)-Sodium Phosphate P322745.0
Other (Cytoreductives)-Thromboreductin2140.0
Other111639.7

Duration of Exposure for Each Essential Thrombocythemia (ET) Therapy

Total duration for each participant = sum of [stop date - start date + 1] across all periods of time where the specific treatment was taken during the study, where start date = registration/consent date for treatments started before registration/consent date and/or stop date withdrawal/final date for treatments ongoing at the time of withdrawal/end of study. Where a participant has multiple records of the same therapy on the same day, the therapy is counted once for that day. (NCT00567502)
Timeframe: Up to 5 years

Interventiondays (Mean)
XAGRID Taken1213.7
Other (Cytoreductives)-Hydroxyurea1382.3
Other (Cytoreductives)-Interferon Alpha933.3
Other (Cytoreductives)-Pegylated Interferon744.0
Other (Cytoreductives)-Busulphan510.2
Other (Cytoreductives)-Pipobroman992.8
Other (Cytoreductives)-Sodium Phosphate P3239.7
Other (Cytoreductives)-Thromboreductin979.0
Other446.3

Event Rate of Thrombohaemorrhagic Events

Event Rate of Thrombohaemorrhagic Events was calculated by dividing number of participants with events by total patient-year exposure. The reporting unit is per 100 participant-years of treatment exposure. Thrombohaemorrhagic Events is a composite endpoint of the PDEs myocardial infarction, angina, stroke, transient ischaemic attack, venous thromboembolic events, intermittent claudication/digital ischaemia, and major haemorrhagic events. (NCT00567502)
Timeframe: Up to 5 years

Interventionparticipants/100 participant-years (Number)
XAGRID Only2.75
XAGRID+Other (Cytoreductives)2.86
Other (Cytoreductives)2.60
No Essential Thrombocythemia (ET) Therapy4.91

Number of Participants With Suspected Serious Adverse Reaction (SSAR) Events

SSAR: serious adverse event (SAE) that was considered related to cytoreductive therapy. SAE: any untoward medical occurrence that at any dose resulted in death, life-threatening (at the time of the event), in-patient hospitalization/prolongation of existing hospitalization (elective hospitalizations/procedures for pre-existing conditions that had not worsened were excluded), resulted in persistent or significant disability/incapacity or congenital abnormality/birth defect. Relatedness (suspected/not suspected) to XAGRID or other cytoreductive theraphy was determined by the investigator. As for SSARs, it was important to consider whether the events were related to XAGRID or other cytoreductive therapy. A participant was included in Xagrid or other treatment group based on treatment exposure, participants received Xagrid + Other was counted both in Xagrid and other treatment group. (NCT00567502)
Timeframe: Up to 5 years

Interventionparticipants (Number)
XAGRID37
Other (Cytoreductives)70

Percentage of Participants With At Least One Pre-Defined Event (PDE), Deaths, Pregnancies

Pre-defined events (PDEs) were evaluated whenever an event occurred and was defined by a panel of independent qualified physicians, blinded to cytoreductive therapy, validated all PDEs prior to analysis (Event Validation Panel). Non-PDE death only included deaths not recorded as outcome of another PDE. (NCT00567502)
Timeframe: Up to 5 years

,,
Interventionpercentage of participants (Number)
Myocardial infarctionAnginaCongestive heart failureCardiomyopathyOther cardiovascular symptomsStrokeTransient ischemic attackSevere Mucocutaneous DisordersPulmonary hypertensionPulmonary fibrosis/ Interstitial pneumoniaVenous thromboembolic eventsPancreatitisIntermittent Claudication/ digital ischaemiaTransformationsMyelofibrosisMyelodysplasiaAcute leukaemiaOther leukaemiaOther transformationsMajor haemorrhagic eventsRhabdomyolysis/ myalgiaNon-haematological malignancyNon-PDE deathPregnancyThrombohaemorrhagic eventsMajor thrombotic eventsArterial events
Other (Cytoreductives)1.50.71.20.33.21.81.32.40.20.31.90.10.63.11.10.51.00.50.11.60.14.63.90.58.57.35.5
XAGRID Only1.00.71.20.55.81.41.10.50.50.10.50.00.74.53.50.00.20.60.13.00.21.52.20.58.15.34.9
XAGRID+Other (Cytoreductives)0.00.01.40.08.51.40.71.40.00.00.00.00.76.45.00.01.40.00.00.70.01.41.40.03.52.82.8

Platelet Count

(NCT00567502)
Timeframe: Baseline, Month 6,12,18, 24, 30, 36, 42, 48, 54, 60

,,,
Intervention10^9 per Liter (10^9/L) (Mean)
Baseline (n = 671, 120, 2279,136)Month 6 (n = 777, 145, 2469, 60)Month 12 (n= 739, 158, 2400, 81)Month 18 (n= 706, 170, 2231, 86)Month 24 (n= 673, 181, 2106, 119)Month 30 (n= 642, 183, 2001, 116)Month 36 (n= 628, 167, 1917, 124)Month 42 (n= 597, 161, 1799, 138)Month 48 (n= 581, 167, 1735, 131)Month 54 (n= 557, 164, 1644, 132)Month 60 (n = 523, 167, 1586, 144)
No Essential Thrombocythemia (ET) Therapy837.23545.30501.46476.72499.29467.54462.06463.52457.44408.41425.22
Other (Cytoreductives)471.29439.44436.64432.991025.11693.301221.091898.481360.171771.771362.94
XAGRID Only486.901093.73969.611612.14865.09418.97423.10831.622461.07413.931174.87
XAGRID+Other (Cytoreductives)542.77521.44516.66541.78492.67467.371138.81466.83443.91447.17466.31

Reviews

69 reviews available for hydroxyurea and Thrombocythemia, Essential

ArticleYear
Treatment options and pregnancy management for patients with PV and ET.
    International journal of hematology, 2022, Volume: 115, Issue:5

    Topics: Aspirin; Female; Humans; Hydroxyurea; Janus Kinase 2; Janus Kinase Inhibitors; Myeloproliferative Di

2022
SURPASS-ET: phase III study of ropeginterferon alfa-2b versus anagrelide as second-line therapy in essential thrombocythemia.
    Future oncology (London, England), 2022, Volume: 18, Issue:27

    Topics: Clinical Trials, Phase III as Topic; Humans; Hydroxyurea; Multicenter Studies as Topic; Quinazolines

2022
BCR::ABL1 negative myeloproliferative neoplasms: A review focused on essential thrombocythemia and polycythemia vera.
    Physiology international, 2023, Sep-05, Volume: 110, Issue:3

    Topics: Aspirin; Humans; Hydroxyurea; Mutation; Polycythemia Vera; Thrombocythemia, Essential

2023
Essential Thrombocythemia Presenting with Recurrent Priapism: A Case Report and Review of Literature.
    The American journal of case reports, 2020, Jul-28, Volume: 21

    Topics: Adult; Antineoplastic Agents; Aspirin; Cytoreduction Surgical Procedures; Humans; Hydroxyurea; Male;

2020
Novel and combination therapies for polycythemia vera and essential thrombocythemia: the dawn of a new era.
    Expert review of hematology, 2020, Volume: 13, Issue:11

    Topics: Bone Marrow; Clinical Trials as Topic; Combined Modality Therapy; DNA Methylation; Drugs, Investigat

2020
Thrombocytosis in children and adolescents-classification, diagnostic approach, and clinical management.
    Annals of hematology, 2021, Volume: 100, Issue:7

    Topics: Adolescent; Adult; Age of Onset; Algorithms; Anticoagulants; Calreticulin; Child; Disease Management

2021
Do All Patients With Polycythemia Vera or Essential Thrombocythemia Need Cytoreduction?
    Journal of the National Comprehensive Cancer Network : JNCCN, 2018, Volume: 16, Issue:12

    Topics: Antineoplastic Agents; Bone Marrow; Cell Proliferation; Evidence-Based Medicine; Hematopoiesis; Huma

2018
Contemporary management of essential thrombocythemia in children.
    Expert review of hematology, 2019, Volume: 12, Issue:5

    Topics: Anticoagulants; Aspirin; Calreticulin; Child; Disease Management; Humans; Hydroxyurea; Interferon-al

2019
[Treatment of essential thrombocythemia].
    Medicina clinica, 2013, Sep-21, Volume: 141, Issue:6

    Topics: Adult; Age Factors; Aged; Anticoagulants; Aspirin; Cell Transformation, Neoplastic; Disease Progress

2013
Paediatric essential thrombocythaemia: clinical and molecular features, diagnosis and treatment.
    British journal of haematology, 2013, Volume: 163, Issue:3

    Topics: Adolescent; Age of Onset; Anticoagulants; Child; Child, Preschool; Clone Cells; Disease Progression;

2013
Therapeutic options for patients with polycythemia vera and essential thrombocythemia refractory/resistant to hydroxyurea.
    Leukemia & lymphoma, 2014, Volume: 55, Issue:12

    Topics: Antineoplastic Agents; Busulfan; Disease Management; Drug Resistance; Histone Deacetylase Inhibitors

2014
Leukemic transformation in myeloproliferative neoplasms: therapy-related or unrelated?
    Best practice & research. Clinical haematology, 2014, Volume: 27, Issue:2

    Topics: Antineoplastic Agents; Cell Transformation, Neoplastic; Disease Progression; Humans; Hydroxyurea; Ja

2014
[Treatment strategy for myeloproliferative neoplasms].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2014, Volume: 55, Issue:10

    Topics: Adrenal Cortex Hormones; Aspirin; Calreticulin; Carbamates; Clinical Trials as Topic; Drug Therapy,

2014
Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management.
    American journal of hematology, 2015, Volume: 90, Issue:2

    Topics: Aspirin; Calreticulin; Diagnosis, Differential; Disease Management; Humans; Hydroxyurea; Janus Kinas

2015
[Fever induced by hydroxycarbamide].
    Medicina clinica, 2015, Dec-07, Volume: 145, Issue:11

    Topics: Aged; Fever; Humans; Hydroxyurea; Male; Myalgia; Recurrence; Thrombocythemia, Essential

2015
Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms.
    Journal of the National Comprehensive Cancer Network : JNCCN, 2015, Volume: 13, Issue:4

    Topics: Antineoplastic Agents; Calreticulin; Hematopoietic Stem Cell Transplantation; Humans; Hydroxyurea; J

2015
Anagrelide compared with hydroxyurea in essential thrombocythemia: a meta-analysis.
    Journal of thrombosis and thrombolysis, 2015, Volume: 40, Issue:4

    Topics: Hemorrhage; Humans; Hydroxyurea; Quinazolines; Thrombocythemia, Essential; Thrombosis

2015
Essential Thrombocythemia: The Dermatologic Point of View.
    Clinical lymphoma, myeloma & leukemia, 2015, Volume: 15, Issue:12

    Topics: Antineoplastic Agents; Humans; Hydroxyurea; Interferon-alpha; Quinazolines; Skin Diseases; Thrombocy

2015
Clinical and histological characteristics of livedo racemosa in essential thrombocythemia: A report of two cases and review of the published works.
    The Journal of dermatology, 2017, Volume: 44, Issue:1

    Topics: Aged; Aspirin; Calreticulin; Humans; Hydroxyurea; Janus Kinase 2; Livedo Reticularis; Male; Middle A

2017
Pharmacotherapy of essential thrombocythemia.
    Expert opinion on pharmacotherapy, 2008, Volume: 9, Issue:10

    Topics: Age Factors; Antineoplastic Agents; Aspirin; Disease Progression; Humans; Hydroxyurea; Interferon-al

2008
Evidence and expertise in the management of polycythemia vera and essential thrombocythemia.
    Leukemia, 2008, Volume: 22, Issue:8

    Topics: Aspirin; Humans; Hydroxyurea; Interferon-alpha; Janus Kinase 2; Mutation; Phlebotomy; Polycythemia V

2008
Long-term management of thrombocytosis in essential thrombocythaemia.
    Annals of hematology, 2009, Volume: 88, Issue:1

    Topics: Algorithms; Antineoplastic Agents; Aspirin; Female; Fibrinolytic Agents; Humans; Hydroxyurea; Interf

2009
Pathogenesis and management of essential thrombocythemia.
    Hematology. American Society of Hematology. Education Program, 2009

    Topics: Acute Disease; Aged; Aspirin; Clone Cells; Disease Management; Disease Progression; Humans; Hydroxyu

2009
Emergence of chronic myelogenous leukemia during treatment for essential thrombocythemia.
    International journal of hematology, 2010, Volume: 91, Issue:3

    Topics: Aged; Antineoplastic Agents; Humans; Hydroxyurea; Leukemia, Myelogenous, Chronic, BCR-ABL Positive;

2010
Hydroxyurea: The drug of choice for polycythemia vera and essential thrombocythemia.
    Current hematologic malignancy reports, 2006, Volume: 1, Issue:2

    Topics: Aged; Agranulocytosis; Alkylating Agents; Clinical Trials as Topic; Combined Modality Therapy; Disea

2006
Do we know more about essential thrombocythemia because of JAK2V617F?
    Current hematologic malignancy reports, 2009, Volume: 4, Issue:1

    Topics: Female; Humans; Hydroxyurea; Janus Kinase 2; Polycythemia Vera; Pregnancy; Pregnancy Complications;

2009
How to manage essential thrombocythemia.
    Leukemia, 2012, Volume: 26, Issue:5

    Topics: Female; Heparin, Low-Molecular-Weight; Humans; Hydroxyurea; Interferon-alpha; Pregnancy; Pregnancy C

2012
Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management.
    American journal of hematology, 2012, Volume: 87, Issue:3

    Topics: Acute Disease; Age Factors; Alkylating Agents; Anticoagulants; Aspirin; Busulfan; Disease Management

2012
Headache in essential thrombocythaemia.
    International journal of clinical practice, 2012, Volume: 66, Issue:10

    Topics: Alkylating Agents; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Headache Disorders;

2012
Essential thrombocythemia (ET): moving from palliation to cure.
    Hematology (Amsterdam, Netherlands), 2002, Volume: 7, Issue:6

    Topics: Female; Humans; Hydroxyurea; Interferon alpha-2; Interferon-alpha; Male; Palliative Care; Pregnancy;

2002
Indications for lowering platelet numbers in essential thrombocythemia.
    Seminars in hematology, 2003, Volume: 40, Issue:1 Suppl 1

    Topics: Age Factors; Drug Therapy, Combination; Humans; Hydroxyurea; Interferon-alpha; Platelet Aggregation

2003
Treatment indications and choice of a platelet-lowering agent in essential thrombocythemia.
    Current hematology reports, 2003, Volume: 2, Issue:3

    Topics: Alkylating Agents; Hemorrhage; Humans; Hydroxyurea; Platelet Aggregation Inhibitors; Platelet Count;

2003
Pharmacotherapy of essential thrombocythaemia: economic considerations.
    Expert opinion on pharmacotherapy, 2003, Volume: 4, Issue:9

    Topics: Age Factors; Antineoplastic Agents; Aspirin; Clinical Trials, Phase II as Topic; Cost-Benefit Analys

2003
Coexistence of chronic lymphocytic leukemia and essential thrombocythemia.
    Leukemia & lymphoma, 2003, Volume: 44, Issue:8

    Topics: Aged; Chromosome Deletion; Chromosomes, Human, Pair 13; Clone Cells; Cytogenetic Analysis; Diagnosis

2003
Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation.
    Haematologica, 2004, Volume: 89, Issue:2

    Topics: Acute Disease; Adult; Aged; Alkylating Agents; Cell Transformation, Neoplastic; Child; Clinical Tria

2004
Thrombocytosis.
    The New England journal of medicine, 2004, Mar-18, Volume: 350, Issue:12

    Topics: Aspirin; Clone Cells; Diagnosis, Differential; Humans; Hydroxyurea; Interferon-alpha; Plasmapheresis

2004
Plasma cell leukemia occurring in a patient with thrombocythemia treated with hydroxyurea and busulphan.
    Leukemia & lymphoma, 2004, Volume: 45, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Membe

2004
Management of the myeloproliferative disorders : distinguishing data from dogma.
    The hematology journal : the official journal of the European Haematology Association, 2004, Volume: 5 Suppl 3

    Topics: Abnormalities, Drug-Induced; Adult; Aged; Anticoagulants; Contraindications; Female; Humans; Hydroxy

2004
The leukemia controversy in myeloproliferative disorders: is it a natural progression of disease, a secondary sequela of therapy, or a combination of both?
    Seminars in hematology, 2004, Volume: 41, Issue:2 Suppl 3

    Topics: Age Factors; Aged; Antineoplastic Agents, Alkylating; Antiviral Agents; Disease Progression; Female;

2004
Anagrelide: a decade of clinical experience with its use for the treatment of primary thrombocythaemia.
    Expert opinion on pharmacotherapy, 2004, Volume: 5, Issue:8

    Topics: Animals; Carcinogens; Clinical Trials as Topic; Drug Therapy, Combination; Heart Diseases; Humans; H

2004
Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia.
    British journal of haematology, 2005, Volume: 128, Issue:3

    Topics: Aged; Aspirin; Hemorrhage; Humans; Hydroxyurea; Middle Aged; Polycythemia Vera; Risk Factors; Thromb

2005
A critical review of anagrelide therapy in essential thrombocythemia and related disorders.
    Leukemia & lymphoma, 2005, Volume: 46, Issue:5

    Topics: Clinical Trials as Topic; Humans; Hydroxyurea; Quinazolines; Thrombocythemia, Essential; Thrombocyto

2005
[Treatment of essential thrombocythemia].
    La Revue de medecine interne, 2005, Volume: 26, Issue:12

    Topics: Aspirin; Enzyme Inhibitors; Hemorrhage; Humans; Hydroxyurea; Immunologic Factors; Interferon-alpha;

2005
Essential thrombocythemia: scientific advances and current practice.
    Current opinion in hematology, 2006, Volume: 13, Issue:2

    Topics: Antineoplastic Agents; Aspirin; Bone Marrow Examination; Humans; Hydroxyurea; In Situ Hybridization,

2006
Management of essential thrombocythemia: implications of the medical research council primary thrombocythemia 1 trial.
    Seminars in thrombosis and hemostasis, 2006, Volume: 32, Issue:3

    Topics: Disease Management; Humans; Hydroxyurea; Quinazolines; Randomized Controlled Trials as Topic; Thromb

2006
Leg ulcers in elderly on hydroxyurea: a single center experience in Ph- myeloproliferative disorders and review of literature.
    Aging clinical and experimental research, 2006, Volume: 18, Issue:3

    Topics: Age Factors; Aged; Aged, 80 and over; Female; Humans; Hydroxyurea; Leg Ulcer; Male; Myeloproliferati

2006
Anagrelide: what was new in 2004 and 2005?
    Seminars in thrombosis and hemostasis, 2006, Volume: 32, Issue:4 Pt 2

    Topics: Antineoplastic Agents; Aspirin; Blood Platelets; Clinical Trials, Phase III as Topic; Drug Therapy,

2006
Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia.
    Seminars in thrombosis and hemostasis, 2006, Volume: 32, Issue:4 Pt 2

    Topics: Antineoplastic Agents, Alkylating; Drug Therapy, Combination; Female; Humans; Hydroxyurea; Interfero

2006
Update on diagnosis and management of essential thrombocythemia.
    Seminars in thrombosis and hemostasis, 2006, Volume: 32, Issue:4 Pt 2

    Topics: Age Factors; Antineoplastic Agents; Aspirin; Drug Antagonism; Female; Fibrinolytic Agents; Hemorrhag

2006
[Primary thrombocythemia: diagnosis and therapy].
    Medizinische Klinik (Munich, Germany : 1983), 2006, Aug-15, Volume: 101, Issue:8

    Topics: Adult; Aged; Aspirin; Child; Diagnosis, Differential; Drug Therapy, Combination; Enzyme Inhibitors;

2006
Evolving management of essential thrombocythaemia.
    European journal of haematology. Supplementum, 2007, Issue:68

    Topics: Cell Transformation, Neoplastic; Humans; Hydroxyurea; Leukemia; Thrombocythemia, Essential; Thrombos

2007
How would I manage a case of essential thrombocythaemia presenting with an ischaemic toe.
    Hematological oncology, 2008, Volume: 26, Issue:1

    Topics: Aspirin; Evidence-Based Medicine; Humans; Hydroxyurea; Interferon-alpha; Ischemia; Janus Kinase 2; M

2008
Primary thrombocythemia: diagnosis, clinical manifestations and management.
    Annals of hematology, 1993, Volume: 67, Issue:2

    Topics: Adolescent; Adult; Aged; Busulfan; Child; Diagnosis, Differential; Female; Hemorrhage; Humans; Hydro

1993
The management of elderly patients with myeloproliferative disorders.
    Hematological oncology, 1993, Volume: 11 Suppl 1

    Topics: Adult; Age Factors; Aged; Bone Marrow Transplantation; Busulfan; Chronic Disease; Humans; Hydroxyure

1993
Essential thrombocythemia and pregnancy.
    Leukemia & lymphoma, 1996, Volume: 22 Suppl 1

    Topics: Abnormalities, Drug-Induced; Abortion, Spontaneous; Aspirin; Busulfan; Combined Modality Therapy; Di

1996
Treatment strategies in essential thrombocythemia. A critical appraisal of various experiences in different centers.
    Leukemia & lymphoma, 1996, Volume: 22 Suppl 1

    Topics: Adult; Aged; Alkylating Agents; Anemia, Megaloblastic; Arrhythmias, Cardiac; Bone Marrow Diseases; B

1996
[A management program for primary thrombocytopenia].
    Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 1999, Sep-30, Volume: 119, Issue:23

    Topics: Adult; Aged; Anticoagulants; Aspirin; Female; Guidelines as Topic; Humans; Hydroxyurea; Interferon T

1999
Treatment of polycythaemia vera and essential thrombocythaemia.
    Bailliere's clinical haematology, 1998, Volume: 11, Issue:4

    Topics: Adult; Aged; Aspirin; Chlorambucil; Disease Progression; Female; Hemorrhage; Humans; Hydroxyurea; In

1998
The pathogenesis and management of essential thrombocythaemia.
    Haematologica, 1999, Volume: 84 Suppl EHA-4

    Topics: Acute Disease; Alkylating Agents; Aspirin; Cardiovascular Diseases; Clone Cells; Gene Expression; He

1999
Treatment of the myeloproliferative disorders with 32P.
    European journal of haematology, 2000, Volume: 65, Issue:1

    Topics: Adult; Aged; Alkylating Agents; Chlorambucil; Clinical Trials as Topic; Combined Modality Therapy; D

2000
A clinical update in polycythemia vera and essential thrombocythemia.
    The American journal of medicine, 2000, Aug-01, Volume: 109, Issue:2

    Topics: Age Factors; Carcinogens; Cell Transformation, Neoplastic; Chronic Disease; Enzyme Inhibitors; Femal

2000
[What vascular events suggest a myeloproliferative disorder?].
    Journal des maladies vasculaires, 2000, Volume: 25, Issue:5

    Topics: Adult; Aged; Alkylating Agents; Arterial Occlusive Diseases; Cross-Sectional Studies; Erythromelalgi

2000
Efficacy and safety of hydroxyurea in patients with essential thrombocythemia.
    Pathologie-biologie, 2001, Volume: 49, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Anemia; Cell Transformation, Neoplastic; Cohort Studies; Female; Fol

2001
Management of patients with essential thrombocythemia: current concepts and perspectives.
    Pathologie-biologie, 2001, Volume: 49, Issue:2

    Topics: Adult; Aged; Aspirin; Case Management; Clinical Trials as Topic; Diagnosis, Differential; Disease Pr

2001
Current treatment practice for essential thrombocythaemia in adults.
    Expert opinion on pharmacotherapy, 2001, Volume: 2, Issue:3

    Topics: Adult; Aspirin; Humans; Hydroxyurea; Interferon-alpha; Pipobroman; Prognosis; Quinazolines; Thromboc

2001
A single institutional experience with 43 pregnancies in essential thrombocythemia.
    European journal of haematology, 2001, Volume: 66, Issue:3

    Topics: Abortion, Induced; Abortion, Spontaneous; Abruptio Placentae; Adult; Anticoagulants; Aspirin; Busulf

2001
[Essential thrombocythemia: conventional therapy].
    Haematologica, 1991, Volume: 76 Suppl 3

    Topics: Adult; Antineoplastic Agents; Busulfan; Follow-Up Studies; Hemorrhage; Humans; Hydroxyurea; Immunolo

1991
The clinical spectrum of thrombocytosis and thrombocythemia.
    The American journal of the medical sciences, 1991, Volume: 301, Issue:1

    Topics: Blood Platelets; Cytokines; Hematopoiesis; Humans; Hydroxyurea; Interferon Type I; Megakaryocytes; P

1991
Essential thrombocythemia.
    Progress in hemostasis and thrombosis, 1991, Volume: 10

    Topics: Abortion, Habitual; Age Factors; Blood Platelets; Combined Modality Therapy; Diagnosis, Differential

1991

Trials

28 trials available for hydroxyurea and Thrombocythemia, Essential

ArticleYear
Symptom burden and quality of life in patients with high-risk essential thrombocythaemia and polycythaemia vera receiving hydroxyurea or pegylated interferon alfa-2a: a post-hoc analysis of the MPN-RC 111 and 112 trials.
    The Lancet. Haematology, 2022, Volume: 9, Issue:1

    Topics: Female; Humans; Hydroxyurea; Interferon-alpha; Male; Polycythemia Vera; Polyethylene Glycols; Qualit

2022
A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia.
    Blood, 2022, 05-12, Volume: 139, Issue:19

    Topics: Disease Progression; Humans; Hydroxyurea; Interferon-alpha; Polycythemia Vera; Thrombocythemia, Esse

2022
A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia.
    Blood, 2022, 05-12, Volume: 139, Issue:19

    Topics: Disease Progression; Humans; Hydroxyurea; Interferon-alpha; Polycythemia Vera; Thrombocythemia, Esse

2022
A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia.
    Blood, 2022, 05-12, Volume: 139, Issue:19

    Topics: Disease Progression; Humans; Hydroxyurea; Interferon-alpha; Polycythemia Vera; Thrombocythemia, Esse

2022
A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia.
    Blood, 2022, 05-12, Volume: 139, Issue:19

    Topics: Disease Progression; Humans; Hydroxyurea; Interferon-alpha; Polycythemia Vera; Thrombocythemia, Esse

2022
Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea.
    Blood, 2019, 10-31, Volume: 134, Issue:18

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Resistance, Neoplasm; Female; Humans; Hy

2019
The poor outcome in high molecular risk, hydroxycarbamide-resistant/intolerant ET is not ameliorated by ruxolitinib.
    Blood, 2019, 12-05, Volume: 134, Issue:23

    Topics: Disease-Free Survival; Drug Resistance; Female; Humans; Hydroxyurea; Male; Nitriles; Pyrazoles; Pyri

2019
Cytoreductive treatment in patients with CALR-mutated essential thrombocythaemia: a study comparing indications and efficacy among genotypes from the Spanish Registry of Essential Thrombocythaemia.
    British journal of haematology, 2021, Volume: 192, Issue:6

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amino Acid Substitution; Calreticulin; Child; Female; Fo

2021
Cardiovascular Safety of Anagrelide Hydrochloride versus Hydroxyurea in Essential Thrombocythaemia.
    Cardiovascular toxicology, 2021, Volume: 21, Issue:3

    Topics: Adolescent; Adult; Aged; Biopsy; Blood Platelets; Bone Marrow Examination; Echocardiography; Europe;

2021
Data-driven analysis of the kinetics of the JAK2V617F allele burden and blood cell counts during hydroxyurea treatment of patients with polycythemia vera, essential thrombocythemia, and primary myelofibrosis.
    European journal of haematology, 2021, Volume: 107, Issue:6

    Topics: Aged; Alleles; Antineoplastic Agents; Blood Cell Count; Cohort Studies; Female; Humans; Hydroxyurea;

2021
Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results.
    Blood, 2017, 10-12, Volume: 130, Issue:15

    Topics: Adult; Aged; Hemoglobins; Humans; Hydroxyurea; Leukocyte Count; Longitudinal Studies; Middle Aged; N

2017
Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide.
    Blood, 2017, 10-26, Volume: 130, Issue:17

    Topics: Adult; Aged; Aged, 80 and over; Disease Progression; Drug Resistance; Female; Hemorrhage; Humans; Hy

2017
Hydroxycarbamide Plus Aspirin Versus Aspirin Alone in Patients With Essential Thrombocythemia Age 40 to 59 Years Without High-Risk Features.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018, 12-01, Volume: 36, Issue:34

    Topics: Adult; Aspirin; Australia; Disease Progression; Dose-Response Relationship, Drug; Drug Administratio

2018
Leukemic transformation and second cancers in 3649 patients with high-risk essential thrombocythemia in the EXELS study.
    Leukemia research, 2018, Volume: 74

    Topics: Adult; Aged; Aged, 80 and over; Cell Transformation, Neoplastic; Female; Humans; Hydroxyurea; Leukem

2018
Cepeginterferon alfa-2b in the treatment of chronic myeloproliferative diseases.
    Terapevticheskii arkhiv, 2018, Aug-17, Volume: 90, Issue:7

    Topics: Adult; Gene Frequency; Humans; Hydroxyurea; Interferon alpha-2; Interferon-alpha; Janus Kinase 2; Mi

2018
Combination therapy of hydroxycarbamide with anagrelide in patients with essential thrombocythemia in the evaluation of Xagrid(R) efficacy and long-term safety study.
    Haematologica, 2014, Volume: 99, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Cell Count; Drug Therapy, Combination; Female; Hum

2014
Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea.
    Annals of hematology, 2014, Volume: 93, Issue:12

    Topics: Aged; Aged, 80 and over; Alkylating Agents; Blood Cell Count; Busulfan; Comorbidity; Disease Progres

2014
Interferon α-2b gains high sustained response therapy for advanced essential thrombocythemia and polycythemia vera with JAK2V617F positive mutation.
    Leukemia research, 2014, Volume: 38, Issue:10

    Topics: Adult; Aged; Female; Humans; Hydroxyurea; Interferon alpha-2; Interferon-alpha; Janus Kinase 2; Kapl

2014
[Efficacy and safety of anagrelide in treatment of essential thrombocythemia: multicenter, randomized controlled clinical trial].
    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2015, Volume: 36, Issue:7

    Topics: Humans; Hydroxyurea; Platelet Aggregation Inhibitors; Platelet Count; Quinazolines; Thrombocythemia,

2015
Hydroxyurea (HU) is effective in reducing JAK2V617F mutated clone size in the peripheral blood of essential thrombocythemia (ET) and polycythemia vera (PV) patients.
    Annals of hematology, 2009, Volume: 88, Issue:7

    Topics: Bone Marrow; Clone Cells; Hematopoietic Stem Cells; Humans; Hydroxyurea; Janus Kinase 2; Mutation, M

2009
Reticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapy.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Jun-20, Volume: 27, Issue:18

    Topics: Biomarkers; Bone Marrow; Hemoglobins; Hemorrhage; Humans; Hydroxyurea; Leukocyte Count; Platelet Agg

2009
Decisional flow with a scoring system to start platelet-lowering treatment in patients with essential thrombocythemia: long-term results.
    International journal of hematology, 2009, Volume: 90, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Aging; Blood Platelets; Cardiovascular Diseases; Clinical Protocols;

2009
The influence of low-dose aspirin and hydroxyurea on platelet-leukocyte interactions in patients with essential thrombocythemia.
    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2009, Volume: 20, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Biomarkers; Blood Platelets; Case-Control Studies; Cell Com

2009
Modulation of JAK2 V617F allele burden dynamics by hydroxycarbamide in polycythaemia vera and essential thrombocythaemia patients.
    British journal of haematology, 2011, Volume: 152, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Alleles; Female; Follow-Up Studies; Genetic Load; Humans; Hydroxyure

2011
Efficacy and safety of cytoreductive therapies in patients with essential thrombocythaemia aged >80 years: an interim analysis of the EXELS study.
    Clinical drug investigation, 2013, Volume: 33, Issue:1

    Topics: Age Factors; Aged, 80 and over; Analysis of Variance; Chi-Square Distribution; Drug Substitution; Eu

2013
Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial.
    Blood, 2013, Mar-07, Volume: 121, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Female; Follow-Up Studies; Humans; Hydroxyurea; Male; Maximum Tolera

2013
Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia.
    The New England journal of medicine, 2005, Jul-07, Volume: 353, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Aspirin; Drug Therapy, Combination; Female; F

2005
Effect of anagrelide on platelet coagulant function in patients with essential thrombocythemia.
    Acta haematologica, 2007, Volume: 118, Issue:4

    Topics: Adult; Aged; Antithrombin III; Aspirin; Drug Therapy, Combination; Female; Fibrin Fibrinogen Degrada

2007
Aspirin seems as effective as myelosuppressive agents in the prevention of rethrombosis in essential thrombocythemia.
    Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 1999, Volume: 5, Issue:2

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Busulfan; Disease-Free Survival; Female; Hemorr

1999
Hydroxyurea treatment reduces haematopoietic progenitor growth and CD34 positive cells in polycythaemia vera and essential thrombocythaemia.
    European journal of haematology, 2000, Volume: 64, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antigens, CD34; Cell Division; Cells, Cultured; Colony-Forming Units

2000
Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial.
    British journal of haematology, 2000, Volume: 110, Issue:3

    Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Busul

2000

Other Studies

208 other studies available for hydroxyurea and Thrombocythemia, Essential

ArticleYear
Utility of Optical Imaging in a Patient With Recurrent, Multifocal Hydroxyurea-Associated Basal Cell Carcinoma.
    Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 2022, Jan-01, Volume: 48, Issue:1

    Topics: Carcinoma, Basal Cell; Female; Head and Neck Neoplasms; Humans; Hydroxyurea; Middle Aged; Neoplasm R

2022
Disease and Clinical Characteristics of Patients With a Clinical Diagnosis of Myelofibrosis Enrolled in the MOST Study.
    Clinical lymphoma, myeloma & leukemia, 2022, Volume: 22, Issue:7

    Topics: Aged; Cohort Studies; Humans; Hydroxyurea; Primary Myelofibrosis; Prospective Studies; Thrombocythem

2022
Essential thrombocythemia and aortic dissection,causal or incidental association?
    Journal de medecine vasculaire, 2022, Volume: 47, Issue:1

    Topics: Aortic Dissection; Humans; Hydroxyurea; Janus Kinase 2; Male; Middle Aged; Polycythemia Vera; Thromb

2022
Hemorrhages in Polycythemia Vera and Essential Thrombocythemia: Epidemiology, Description, and Risk Factors-Learnings from a Large Cohort.
    Thrombosis and haemostasis, 2022, Volume: 122, Issue:10

    Topics: Aspirin; Hemorrhage; Humans; Hydroxyurea; Male; Polycythemia Vera; Risk Factors; Thrombocythemia, Es

2022
Cytoreductive treatment and association with platelet function and maturity in patients with essential thrombocythaemia.
    British journal of haematology, 2022, Volume: 198, Issue:4

    Topics: Aspirin; Blood Platelets; Humans; Hydroxyurea; Platelet Aggregation; Platelet Function Tests; Thromb

2022
Prevalence and clinical outcomes of polycythemia vera and essential thrombocythemia with hydroxyurea resistance or intolerance.
    Hematology (Amsterdam, Netherlands), 2022, Volume: 27, Issue:1

    Topics: Humans; Hydroxyurea; Janus Kinase 2; Middle Aged; Polycythemia Vera; Prevalence; Retrospective Studi

2022
Second malignancies among older patients with classical myeloproliferative neoplasms treated with hydroxyurea.
    Blood advances, 2023, 03-14, Volume: 7, Issue:5

    Topics: Aged; Aged, 80 and over; Humans; Hydroxyurea; Leukemia, Myeloid, Acute; Medicare; Myelodysplastic Sy

2023
A Retrospective Chart Review of 809 Patients with Physician-Diagnosed Essential Thrombocythemia Receiving Cytoreductive Therapy in US Community Oncology Practices.
    Acta haematologica, 2023, Volume: 146, Issue:1

    Topics: Aged; Bone Marrow; Cytoreduction Surgical Procedures; Female; Humans; Hydroxyurea; Janus Kinase 2; M

2023
Prediction of thrombosis in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study on 1258 patients.
    Leukemia, 2022, Volume: 36, Issue:10

    Topics: Humans; Hydroxyurea; Janus Kinase Inhibitors; Polycythemia Vera; Primary Myelofibrosis; Thrombocythe

2022
Prognostic value of modified criteria for hydroxyurea resistance or intolerance in patients with high-risk essential thrombocythemia.
    Cancer medicine, 2023, Volume: 12, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Humans; Hydroxyurea; Middle Aged; Prognosis; Retrospective Studies;

2023
Machine learning analyses constructed a novel model to predict recurrent thrombosis in adults with essential thrombocythemia.
    Journal of thrombosis and thrombolysis, 2023, Volume: 56, Issue:2

    Topics: Adult; Humans; Hydroxyurea; Platelet Aggregation Inhibitors; Risk Factors; Thrombocythemia, Essentia

2023
Clinical features and current treatment status of essential thrombocythemia in older adults: a multicenter real-world study in China.
    Annals of hematology, 2023, Volume: 102, Issue:8

    Topics: Aged; Calreticulin; Humans; Hydroxyurea; Janus Kinase 2; Mutation; Retrospective Studies; Thrombocyt

2023
Pseudohyperkalemia-Not Always Benign.
    The journal of applied laboratory medicine, 2019, Volume: 3, Issue:6

    Topics: Aged, 80 and over; Diagnosis, Differential; Enzyme Inhibitors; Female; Humans; Hydroxyurea; Hyperkal

2019
Reducing the burden of MPN.
    Blood, 2019, 10-31, Volume: 134, Issue:18

    Topics: Humans; Hydroxyurea; Interferon-alpha; Polycythemia Vera; Polyethylene Glycols; Recombinant Proteins

2019
Limb gangrene: The first sign of essential thrombocythemia.
    The Indian journal of medical research, 2020, Volume: 151, Issue:4

    Topics: Aged, 80 and over; Amputation, Surgical; Aspirin; Female; Gangrene; Humans; Hydroxyurea; Leg; Platel

2020
Anagrelide influences thrombotic risk, and prolongs progression-free and overall survival in essential thrombocythaemia vs hydroxyurea plus aspirin.
    European journal of haematology, 2020, Volume: 105, Issue:4

    Topics: Aspirin; Drug Therapy, Combination; Health Care Surveys; Humans; Hungary; Hydroxyurea; Quinazolines;

2020
Intracoronary cangrelor administration-assisted primary percutaneous coronary intervention in a patient with essential thrombocythemia and recurrent ST-segment elevation myocardial infarction.
    Journal of cardiovascular medicine (Hagerstown, Md.), 2020, Volume: 21, Issue:10

    Topics: Adenosine Monophosphate; Adult; Angioplasty, Balloon, Coronary; Coronary Thrombosis; Drug-Eluting St

2020
[Development of skin squamous cell carcinoma on the scalp in a hydroxycarbamide-treated polycythemia vera patient].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2020, Volume: 61, Issue:12

    Topics: Aged; Carcinoma, Squamous Cell; Humans; Hydroxyurea; Polycythemia Vera; Scalp; Thrombocythemia, Esse

2020
Multiple aortic thrombi in essential thrombocythaemia.
    British journal of haematology, 2021, Volume: 193, Issue:5

    Topics: Aged; Aorta, Abdominal; Aspirin; Cefazolin; Echocardiography; Heparin; Humans; Hydroxyurea; Male; St

2021
Treatment of Essential Thrombocythemia with Anagrelide Is Associated with an Increased Risk of Worsened Kidney Function.
    Pharmacology, 2021, Volume: 106, Issue:5-6

    Topics: Aged; Calreticulin; Creatinine; Disease Progression; Female; Humans; Hydroxyurea; Janus Kinase 2; Ki

2021
Lenalidomide: A double-edged sword for concomitant multiple myeloma and post-essential thrombocythemia myelofibrosis.
    American journal of hematology, 2021, 06-01, Volume: 96, Issue:6

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Bone Marrow; Calreticulin; Dexamethas

2021
Modifying the Effects of Cytoreductive Drugs on Kidney Function in Myeloproliferative Neoplasms.
    Pharmacology, 2021, Volume: 106, Issue:7-8

    Topics: Humans; Hydroxyurea; Kidney Function Tests; Myeloproliferative Disorders; Platelet Aggregation Inhib

2021
Evaluation of the need for cytoreduction and its potential carcinogenicity in children and young adults with myeloproliferative neoplasms.
    Annals of hematology, 2021, Volume: 100, Issue:10

    Topics: Adolescent; Adult; Antineoplastic Agents; Aspirin; Child; Female; Fibrinolytic Agents; Follow-Up Stu

2021
IRF4 and IRF8 expression are associated with clinical phenotype and clinico-hematological response to hydroxyurea in essential thrombocythemia.
    Frontiers of medicine, 2022, Volume: 16, Issue:3

    Topics: Biomarkers; Humans; Hydroxyurea; Interferon Regulatory Factors; Janus Kinase 2; Leukemia, Myeloid, A

2022
Hemorrhage and Infarction of the Conjunctiva and Orbit in Essential Thrombocythemia.
    The Journal of craniofacial surgery, 2017, Volume: 28, Issue:3

    Topics: Aged, 80 and over; Biopsy; Conjunctiva; Eye Hemorrhage; Female; Hematologic Agents; Humans; Hydroxyu

2017
Role of treatment on the development of secondary malignancies in patients with essential thrombocythemia.
    Cancer medicine, 2017, Volume: 6, Issue:6

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alkylating Agents; Antineoplastic Combined Chemotherapy

2017
A Violaceous, Photodistributed Cutaneous Eruption and Leg Ulcer in a Woman With Essential Thrombocytosis.
    JAMA dermatology, 2018, 01-01, Volume: 154, Issue:1

    Topics: Aged; Biopsy, Needle; Dermatomyositis; Exanthema; Female; Follow-Up Studies; Humans; Hydroxyurea; Im

2018
Acute renal infarction: a presentation of essential thrombocytosis.
    Kidney international, 2017, Volume: 92, Issue:5

    Topics: Acute Disease; Adult; Anticoagulants; Biopsy; Bone Marrow; Contrast Media; Female; Glomerular Filtra

2017
Ventricular tachyarrhythmia in a 78-year-old woman with essential thrombocythaemia.
    BMJ case reports, 2018, Feb-08, Volume: 2018

    Topics: Age Factors; Aged; Electrocardiography; Female; Humans; Hydroxyurea; Platelet Aggregation Inhibitors

2018
Pegylated interferon Alfa-2a and hydroxyurea in polycythemia vera and essential thrombocythemia: differential cellular and molecular responses.
    Leukemia, 2018, Volume: 32, Issue:8

    Topics: Antineoplastic Agents; Antiviral Agents; Humans; Hydroxyurea; Interferon-alpha; Janus Kinase 2; Muta

2018
Long-term and low-dose of busulfan is a safe and effective second-line treatment in elderly patients with essential thrombocythemia resistant or intolerant to hydroxyurea.
    Blood cancer journal, 2018, 06-11, Volume: 8, Issue:6

    Topics: Age Factors; Aged; Antineoplastic Agents, Alkylating; Busulfan; Drug Resistance; Female; Humans; Hyd

2018
Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management.
    American journal of hematology, 2019, Volume: 94, Issue:1

    Topics: Adult; Aspirin; Bone Marrow; Busulfan; Disease Management; Disease Progression; Hemorrhage; Humans;

2019
Does hydroxycarbamide therapy really induce leukemic transformation in patients with essential thrombocythemia?
    Leukemia research, 2019, Volume: 76

    Topics: Cell Transformation, Neoplastic; Disease Progression; Humans; Hydroxyurea; Thrombocythemia, Essentia

2019
Impact of Hydroxyurea on Survival and Risk of Thrombosis Among Older Patients With Essential Thrombocythemia.
    Journal of the National Comprehensive Cancer Network : JNCCN, 2019, 03-01, Volume: 17, Issue:3

    Topics: Aged; Aged, 80 and over; Female; Health Care Surveys; Humans; Hydroxyurea; Kaplan-Meier Estimate; Ma

2019
[Symptomatic Profiles of 173 Chinese Patients with Essential Thrombocythemia].
    Zhongguo shi yan xue ye xue za zhi, 2019, Volume: 27, Issue:2

    Topics: Asian People; Calreticulin; Female; Humans; Hydroxyurea; Janus Kinase 2; Mutation; Thrombocythemia,

2019
Treatment of Philadelphia-negative myeloproliferative neoplasms in accelerated/blastic phase with azacytidine. Clinical results and identification of prognostic factors.
    Hematological oncology, 2019, Volume: 37, Issue:3

    Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Blast Crisis; Female; Humans; Hydroxyurea; Leuke

2019
Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study.
    Leukemia, 2019, Volume: 33, Issue:8

    Topics: Antineoplastic Agents; Case-Control Studies; Humans; Hydroxyurea; Neoplasms, Second Primary; Nitrile

2019
Clinical Evaluation of the Efficacy and Safety of Anagrelide Used with or without Hydroxycarbamide in Japanese Patients with Essential Thrombocythemia-A Retrospective Single-Center Study of 35 Cases.
    Gan to kagaku ryoho. Cancer & chemotherapy, 2019, Volume: 46, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Hydroxyurea; Japan; Quinazolines; Retrospect

2019
Dysplasia of all granulocyte lineages in myelodysplastic evolution of essential thrombocythemia.
    American journal of hematology, 2013, Volume: 88, Issue:5

    Topics: Aged; Amino Acid Substitution; Antineoplastic Agents; Aspirin; Bone Marrow; Cell Lineage; Cell Trans

2013
Genetic predisposition to molecular response in patients with myeloproliferative neoplasms treated with hydroxycarbamide.
    Leukemia research, 2013, Volume: 37, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Arginase; Female; Gene Frequency; Genetic Pre

2013
The therapeutic goals of essential thrombocythemia under the clouds of over-treatment and under-treatment.
    Expert opinion on pharmacotherapy, 2013, Volume: 14, Issue:11

    Topics: Aspirin; Fibrinolytic Agents; Humans; Hydroxyurea; Interferon-alpha; Platelet Aggregation Inhibitors

2013
Portal biliopathy diagnosed using color Doppler and contrast-enhanced ultrasound.
    Internal medicine (Tokyo, Japan), 2013, Volume: 52, Issue:10

    Topics: Cholangiocarcinoma; Cholangitis, Sclerosing; Cholestasis, Extrahepatic; Collateral Circulation; Comm

2013
Deliberate hydroxycarbamide overdose in an adult with essential thrombocythaemia.
    British journal of haematology, 2013, Volume: 163, Issue:2

    Topics: Critical Care; Drug Overdose; Female; Humans; Hydroxyurea; Middle Aged; Nucleic Acid Synthesis Inhib

2013
High-dose melphalan produces favorable response in a patient with multiple myeloma and coexisting essential thrombocythemia with JAK2 mutation.
    Bone marrow transplantation, 2014, Volume: 49, Issue:1

    Topics: Bone Marrow; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; He

2014
Complex subclone structure that responds differentially to therapy in a patient with essential thrombocythemia and chronic myeloid leukemia.
    Blood, 2013, Nov-21, Volume: 122, Issue:22

    Topics: Clone Cells; Dasatinib; Female; Genes, abl; Humans; Hydroxyurea; Janus Kinase 2; Leukemia, Myelogeno

2013
[A preschool child with primary thrombocytosis].
    Zhonghua er ke za zhi = Chinese journal of pediatrics, 2013, Volume: 51, Issue:7

    Topics: Aspirin; Blood Cell Count; Blood Platelets; C-Reactive Protein; Child, Preschool; Diagnosis, Differe

2013
Successful long-term treatment of Philadelphia chromosome-negative myeloproliferative neoplasms with combination of hydroxyurea and anagrelide.
    Clinical lymphoma, myeloma & leukemia, 2013, Volume: 13 Suppl 2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Hydr

2013
Successful management of acute bleeding in essential thrombocythemia using automated cell separator.
    Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis, 2014, Volume: 50, Issue:1

    Topics: Administration, Oral; Adolescent; Automation; Blood Platelets; Body Weight; Cell Separation; Female;

2014
Perspectives on the impact of JAK-inhibitor therapy upon inflammation-mediated comorbidities in myelofibrosis and related neoplasms.
    Expert review of hematology, 2014, Volume: 7, Issue:2

    Topics: Chronic Disease; Comorbidity; Humans; Hydroxyurea; Inflammation; Interferon alpha-2; Interferon-alph

2014
Interferon apha 2b for treating patients with JAK2V617F positive polycythemia vera and essential thrombocytosis.
    Asian Pacific journal of cancer prevention : APJCP, 2014, Volume: 15, Issue:4

    Topics: Adult; Aged; Female; Humans; Hydroxyurea; Interferon alpha-2; Interferon-alpha; Janus Kinase 2; Male

2014
Expansion of circulating CD56bright natural killer cells in patients with JAK2-positive chronic myeloproliferative neoplasms during treatment with interferon-α.
    European journal of haematology, 2015, Volume: 94, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Case-Control Studies; CD56 Antigen; Female; G

2015
Essential differences in clinical and bone marrow features in BCR/ABL-positive thrombocythemia compared to thrombocythemia in the BCR/ABL-negative myeloproliferative neoplasms essential thrombocythemia and polycythemia vera.
    Acta haematologica, 2015, Volume: 133, Issue:1

    Topics: Aged; Alleles; Benzamides; Biopsy; Bone Marrow; Diagnosis, Differential; Drug Therapy, Combination;

2015
Consequences of the JAK2V617F allele burden for the prediction of transformation into myelofibrosis from polycythemia vera and essential thrombocythemia.
    International journal of hematology, 2015, Volume: 101, Issue:2

    Topics: Alleles; Bone Marrow; Disease Progression; Humans; Hydroxyurea; Janus Kinase 2; Mutation; Polycythem

2015
Essential thrombocythaemia.
    Hematology (Amsterdam, Netherlands), 2015, Volume: 20, Issue:2

    Topics: Age Factors; Antineoplastic Agents; Blood Platelets; Calreticulin; Gene Expression; Humans; Hydroxyu

2015
Prediction of thrombotic and hemorrhagic events during polycythemia vera or essential thrombocythemia based on leukocyte burden.
    Thrombosis research, 2015, Volume: 135, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Area Under Curve; Blood Cell Count; Comorbidity; Databases, Factual;

2015
New and treatment-relevant risk stratification for thrombosis in essential thrombocythemia and polycythemia vera.
    American journal of hematology, 2015, Volume: 90, Issue:8

    Topics: Age Factors; Aged; Aspirin; Drug Administration Schedule; Enzyme Inhibitors; Fibrinolytic Agents; Hu

2015
Qualitative and quantitative modifications of von Willebrand factor in patients with essential thrombocythemia and controlled platelet count.
    Journal of thrombosis and haemostasis : JTH, 2015, Volume: 13, Issue:7

    Topics: ADAM Proteins; ADAM10 Protein; ADAM17 Protein; Aged; Amyloid Precursor Protein Secretases; Aspirin;

2015
Reactivation of hepatitis B virus during treatment with hydroxyurea in an elderly patient with essential thrombocythemia.
    Geriatrics & gerontology international, 2015, Volume: 15, Issue:6

    Topics: Aged; Antineoplastic Agents; Carrier State; Female; Hepatitis B virus; Humans; Hydroxyurea; Thromboc

2015
Comparative long-term effects of interferon α and hydroxyurea on human hematopoietic progenitor cells.
    Experimental hematology, 2015, Volume: 43, Issue:10

    Topics: Aged; Animals; Cell Differentiation; Cell Proliferation; Female; Hematopoietic Stem Cells; Humans; H

2015
Acral keratoses and leucocytoclastic vasculitis occurring during treatment of essential thrombocythaemia with hydroxyurea.
    Clinical and experimental dermatology, 2016, Volume: 41, Issue:2

    Topics: Aged; Enzyme Inhibitors; Female; Foot Dermatoses; Humans; Hydroxyurea; Keratosis; Thrombocythemia, E

2016
Clinical and molecular response to interferon-α therapy in essential thrombocythemia patients with CALR mutations.
    Blood, 2015, Dec-10, Volume: 126, Issue:24

    Topics: Adolescent; Adult; Alleles; Aspirin; Calreticulin; Clonal Evolution; Clone Cells; Dioxygenases; DNA

2015
Assessment of rotation thromboelastometry parameters in patients with essential thrombocythemia at diagnosis and after hydroxyurea therapy.
    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2016, Volume: 27, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Blood Platelets; Case-Control Studies; Clot Retraction; Erythrocyte

2016
[Treatment outcome of patients with essential thrombocythemia at our department in Hungary].
    Orvosi hetilap, 2016, Feb-28, Volume: 157, Issue:9

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Adm

2016
Current opinion and consensus statement regarding the diagnosis, prognosis, and treatment of patients with essential thrombocythemia: a survey of the Spanish Group of Ph-negative Myeloproliferative Neoplasms (GEMFIN) using the Delphi method.
    Annals of hematology, 2016, Volume: 95, Issue:5

    Topics: Bone Marrow Examination; Delphi Technique; Diagnosis, Differential; Disease Management; DNA Mutation

2016
Multicenter Retrospective Analysis of Turkish Patients with Chronic Myeloproliferative Neoplasms.
    Turkish journal of haematology : official journal of Turkish Society of Haematology, 2017, Mar-01, Volume: 34, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Chronic Disease; Fe

2017
Acute pancreatitis as a side effect of anagrelide hydrochloride hydrate: a case report.
    Annals of hematology, 2016, Volume: 95, Issue:11

    Topics: Abdominal Pain; Acute Disease; Aged; Aspirin; Drug Substitution; Female; Humans; Hydroxyurea; Janus

2016
Refractory Arterial Insufficiency Associated with Janus Kinase 2 Positive Essential Thrombocythaemia.
    Annals of vascular surgery, 2017, Volume: 38

    Topics: Amputation, Surgical; Angioplasty, Balloon; Anti-Bacterial Agents; Arterial Occlusive Diseases; Comp

2017
Incidence, Survival and Prevalence Statistics of Classical Myeloproliferative Neoplasm in Korea.
    Journal of Korean medical science, 2016, Volume: 31, Issue:10

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Child, Preschool; Databases, Factual; Drug Prescr

2016
Anagrelide reduces thrombotic risk in essential thrombocythaemia vs. hydroxyurea plus aspirin.
    European journal of haematology, 2017, Volume: 98, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Aspirin; Drug Therapy, Combination; Female; Follow-Up Studies; Human

2017
Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management.
    American journal of hematology, 2017, Volume: 92, Issue:1

    Topics: Aspirin; Calreticulin; Diagnosis, Differential; Erythropoietin; Humans; Hydroxyurea; Interferon-alph

2017
Observational retrospective study of vascular modulator changes during treatment in essential thrombocythemia.
    Translational research : the journal of laboratory and clinical medicine, 2017, Volume: 184

    Topics: Adrenomedullin; Aged; Aspirin; Blood Platelets; Case-Control Studies; Cell-Derived Microparticles; E

2017
Medical Management of Extensive Arterial Thromboembolism in a Patient with Essential Thrombocythemia and Warfarin Failure.
    Annals of vascular surgery, 2017, Volume: 42

    Topics: Anticoagulants; Arterial Occlusive Diseases; Blood Coagulation; Blood Coagulation Tests; Computed To

2017
Rapid decline of JAK2V617F levels during hydroxyurea treatment in patients with polycythemia vera and essential thrombocythemia.
    Haematologica, 2008, Volume: 93, Issue:8

    Topics: Aged; Aged, 80 and over; Amino Acid Substitution; Antisickling Agents; Female; Humans; Hydroxyurea;

2008
Management of femoral fracture in a patient with essential thrombocythemia treated with plateletpheresis and intramedullary rod fixation, followed by hydroxyurea: a case report.
    The American journal of emergency medicine, 2008, Volume: 26, Issue:5

    Topics: Aged; Comorbidity; Emergency Medical Services; Femoral Fractures; Fracture Fixation, Intramedullary;

2008
Frequent reduction or absence of detection of the JAK2-mutated clone in JAK2V617F-positive patients within the first years of hydroxyurea therapy.
    Haematologica, 2008, Volume: 93, Issue:11

    Topics: Aged; Aged, 80 and over; Amino Acid Substitution; Antisickling Agents; Cohort Studies; DNA Primers;

2008
Second malignancies in essential thrombocythemia (ET): a retrospective analysis of 331 patients with long-term follow-up from a single institution.
    Hematology (Amsterdam, Netherlands), 2008, Volume: 13, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alkylating Agents; Busulfan; Drug Therapy, Combination;

2008
Hydroxyurea in old patients with essential thrombocythemia.
    Aging clinical and experimental research, 2008, Volume: 20, Issue:4

    Topics: Aged; Disease-Free Survival; Female; Humans; Hydroxyurea; Male; Thrombocythemia, Essential

2008
Hydroxyurea and anagrelide combination therapy in patients with chronic myeloproliferative diseases resistant or intolerant to monotherapy.
    Acta haematologica, 2008, Volume: 120, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Drug Resistance; Drug Therapy, Combination; Female; Humans; Hydroxyu

2008
Correlation between leukocytosis and thrombosis in Philadelphia-negative chronic myeloproliferative neoplasms.
    Annals of hematology, 2009, Volume: 88, Issue:10

    Topics: Aged; Female; Humans; Hydroxyurea; Janus Kinase 2; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Neg

2009
Essential thrombocythemia: a case of acute ST-segment elevation myocardial infarction in a young female.
    Clinical cardiology, 2009, Volume: 32, Issue:2

    Topics: Adult; Age Factors; Antisickling Agents; Aspirin; Clopidogrel; Coronary Angiography; Female; Fibrino

2009
JAK2 V617F-positive latent essential thrombocythemia and splanchnic vein thrombosis: the role of bone marrow biopsy for the diagnosis of myeloproliferative disease.
    Acta haematologica, 2009, Volume: 121, Issue:4

    Topics: Abdominal Pain; Acenocoumarol; Adult; Anticoagulants; Biopsy; Bone Marrow; Bone Marrow Examination;

2009
JAK2V617F mutation-positive childhood essential thrombocythemia associated with cerebral venous sinus thrombosis.
    Journal of pediatric hematology/oncology, 2009, Volume: 31, Issue:9

    Topics: Aspirin; Child; Clone Cells; Cytotoxins; Diagnosis, Differential; Female; Headache; Humans; Hydroxyu

2009
Essential thrombocythemia and pregnancy: Observations from recent studies and management recommendations.
    American journal of hematology, 2009, Volume: 84, Issue:10

    Topics: Aspirin; Female; Heparin, Low-Molecular-Weight; Humans; Hydroxyurea; Interferon Type I; Pregnancy; P

2009
Essential thrombocythemia transforming into acute biphenotypic leukemia in a patient on hydroxyurea monotherapy.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2009, Volume: 20, Issue:11

    Topics: Aged; Antineoplastic Agents; Cell Transformation, Neoplastic; Female; Humans; Hydroxyurea; Leukemia,

2009
Images in clinical medicine. Acquired melanonychia.
    The New England journal of medicine, 2009, Sep-17, Volume: 361, Issue:12

    Topics: Aged, 80 and over; Diagnosis, Differential; Female; Humans; Hydroxyurea; Nail Diseases; Pigmentation

2009
[Multiple, painful, treatment-resistant leg ulcers associated with dermatomyositis-like lesions over the interphalangeal joints induced by hydroxyurea].
    Actas dermo-sifiliograficas, 2009, Volume: 100, Issue:9

    Topics: Aged; Dermatomyositis; Female; Hand Dermatoses; Humans; Hydroxyurea; Interferon alpha-2; Interferon-

2009
Acute coronary syndrome associated with essential thrombocythemia.
    Journal of cardiology, 2009, Volume: 54, Issue:3

    Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Coronary Thrombosis; Drug Therapy, Combinat

2009
Management of refractory essential thrombocythemia with anagrelide in a patient undergoing hemodialysis.
    Clinical therapeutics, 2009, Volume: 31, Issue:11

    Topics: Aged; Aspirin; Blood Cell Count; Blood Chemical Analysis; Blood Transfusion; Drug Resistance; Erythr

2009
Essential thrombocythaemia in a teenage girl resulting in acquired von Willebrand syndrome with joint haemorrhage and menorrhagia.
    Thrombosis and haemostasis, 2010, Volume: 103, Issue:6

    Topics: Adolescent; Antigens, CD34; Blood Cell Count; Blood Platelets; Female; Hemorrhage; Humans; Hydroxyur

2010
Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia.
    Haematologica, 2010, Volume: 95, Issue:8

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alleles; Amino Acid Substitution; Female; Gene Frequency

2010
Nitric oxide derivatives and soluble plasma selectins in patients with myeloproliferative neoplasms.
    Thrombosis and haemostasis, 2010, Volume: 104, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; DNA Mutational Analysis; E-Selectin; Endothelium, Va

2010
Hydroxyurea in essential thrombocythemia: rate and clinical relevance of responses by European LeukemiaNet criteria.
    Blood, 2010, Aug-19, Volume: 116, Issue:7

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Hydroxyurea; Male

2010
Plasma levels of angiogenic factors and circulating endothelial cells in essential thrombocythemia: correlation with cytoreductive therapy and JAK2-V617F mutational status.
    Leukemia & lymphoma, 2010, Volume: 51, Issue:9

    Topics: Adult; Aged; Aged, 80 and over; Angiogenic Proteins; Antineoplastic Agents; Apoptosis; Case-Control

2010
Prognostic utility of spontaneous erythroid colony formation and JAK2 mutational analysis for thrombotic events in essential thrombocythaemia.
    Internal medicine journal, 2011, Volume: 41, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Colony-Forming Units Assay; DNA Mutational Analysis; Erythroid Precu

2011
Hydroxyurea-induced foot ulcer in a case of essential thrombocythaemia.
    Journal of wound care, 2010, Volume: 19, Issue:8

    Topics: Aged; Biopsy; Blood Gas Monitoring, Transcutaneous; Drug Monitoring; Erythrocyte Indices; Female; Fo

2010
Bone marrow failure due to T-cell large granular lymphocytic leukemia in a patient with essential thrombocythemia.
    Leukemia research, 2011, Volume: 35, Issue:2

    Topics: Aged, 80 and over; Antineoplastic Agents; Female; Humans; Hydroxyurea; Leukemia, Large Granular Lymp

2011
Clinical evaluation of the European LeukaemiaNet criteria for clinicohaematological response and resistance/intolerance to hydroxycarbamide in essential thrombocythaemia.
    British journal of haematology, 2011, Volume: 152, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Drug Evaluation; Drug Resistance; Epidemiologic Methods;

2011
Thrombocytosis in rheumatoid arthritis: JAK2V617F-positive essential thrombocythemia.
    Rheumatology international, 2012, Volume: 32, Issue:1

    Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Aspirin; Comorbidity; Humans; Hydroxyurea; Janus Kinase

2012
Differential expression of JAK2 and Src kinase genes in response to hydroxyurea treatment in polycythemia vera and essential thrombocythemia.
    Annals of hematology, 2011, Volume: 90, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Case-Control Studies; Female; Gene Expression Profiling; Gene Expres

2011
Hydroxyurea dose impacts hematologic parameters in polycythemia vera and essential thrombocythemia but does not appreciably affect JAK2-V617F allele burden.
    Haematologica, 2011, Volume: 96, Issue:3

    Topics: Alleles; Antineoplastic Agents; Dose-Response Relationship, Drug; Gene Frequency; Granulocytes; Hema

2011
Clearance of circulating activated platelets in polycythemia vera and essential thrombocythemia.
    Blood, 2011, Sep-22, Volume: 118, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Animals; Blood Platelets; Case-Control Studies; Female; Flow Cytomet

2011
Increase in circulating CD4⁺CD25⁺Foxp3⁺ T cells in patients with Philadelphia-negative chronic myeloproliferative neoplasms during treatment with IFN-α.
    Blood, 2011, Aug-25, Volume: 118, Issue:8

    Topics: Adult; Aged; Antineoplastic Agents; Female; Forkhead Transcription Factors; Humans; Hydroxyurea; Int

2011
JAK2V617F mutation and hydroxyurea treatment as determinants of immature platelet parameters in essential thrombocythemia and polycythemia vera patients.
    Blood, 2011, Sep-01, Volume: 118, Issue:9

    Topics: Blood Platelets; Humans; Hydroxyurea; Janus Kinase 2; Mutation, Missense; Phenotype; Platelet Count;

2011
Direct evidence for normalization of platelet function resulting from platelet count reduction in essential thrombocythemia.
    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2011, Volume: 22, Issue:6

    Topics: Adenosine Diphosphate; Adult; Aspirin; Blood Platelets; Collagen; Epinephrine; Female; Greece; Human

2011
Toenails melanonychia induced by hydroxyurea.
    Presse medicale (Paris, France : 1983), 2012, Volume: 41, Issue:4

    Topics: Aged; Antisickling Agents; Diagnosis, Differential; Drug Eruptions; Female; Humans; Hydroxyurea; Hyp

2012
Circulating endothelial cells and endothelial activation in essential thrombocythemia: results from CD146+ immunomagnetic enrichment--flow cytometry and soluble E-selectin detection.
    American journal of hematology, 2012, Volume: 87, Issue:3

    Topics: Alkylating Agents; Anticoagulants; Aspirin; CD146 Antigen; Drug Therapy, Combination; E-Selectin; En

2012
Prognostic implications of leg ulcers from hydroxycarbamide therapy in patients with essential thrombocythaemia.
    Leukemia research, 2012, Volume: 36, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Enzyme Inhibitors; Female; Humans; Hydroxyurea; Leg Ulcer; Male; Mid

2012
Cerebral infarct in a patient with a history of systemic arterial and venous thrombosis from essential thrombocythemia.
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2012, Volume: 21, Issue:8

    Topics: Arterial Occlusive Diseases; Biopsy; Bone Marrow Examination; Cerebral Angiography; Cerebral Infarct

2012
Impaired apoptosis of megakaryocytes and bone marrow mononuclear cells in essential thrombocythemia: correlation with JAK2V617F mutational status and cytoreductive therapy.
    Medical oncology (Northwood, London, England), 2012, Volume: 29, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Apoptosis; Bone Marrow Cells; Female; Humans; Hydroxyurea; Janus Kin

2012
Bilateral vertebral artery dissection and essential thrombocythemia with JAK2 mutation.
    Revue neurologique, 2012, Volume: 168, Issue:6-7

    Topics: Adult; Anticoagulants; Antineoplastic Agents; Brain Ischemia; Diplopia; Female; Humans; Hydroxyurea;

2012
Repeated episodes of ischemic stroke over a short period in a patient with essential thrombocythemia on anticoagulant therapy.
    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 2014, Volume: 23, Issue:1

    Topics: Aged; Anticoagulants; Aphasia; Brain Ischemia; Cerebral Angiography; Cilostazol; Diffusion Magnetic

2014
Homoharringtonine is an effective therapy for patients with polycythemia vera or essential thrombocythemia who have failed or were intolerant to hydroxycarbamide or interferon-α therapy.
    International journal of clinical oncology, 2013, Volume: 18, Issue:5

    Topics: Adult; Aged; Cephalotaxus; Dose-Response Relationship, Drug; Female; Harringtonines; Homoharringtoni

2013
Two cases of pediatric essential thrombocythemia managed effectively with hydroxyurea.
    International journal of hematology, 2012, Volume: 96, Issue:6

    Topics: Aspirin; Asymptomatic Diseases; Bone Marrow; Child; Child, Preschool; Female; Headache; Humans; Hydr

2012
Comparison of coated-platelet levels in patients with essential thrombocythemia with and without hydroxyurea treatment.
    Platelets, 2013, Volume: 24, Issue:6

    Topics: Adult; Aged; Blood Platelets; Case-Control Studies; Female; Humans; Hydroxyurea; Janus Kinase 2; Mal

2013
Clinical evaluation of the European LeukemiaNet response criteria in patients with essential thrombocythemia treated with anagrelide.
    Annals of hematology, 2013, Volume: 92, Issue:6

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Biomarkers; Disease-Free Survival; Female; Follow-Up Stu

2013
Increased CD11/CD18 expression and altered metabolic activity on polymorphonuclear leukocytes from patients with polycythemia vera and essential thrombocythemia.
    Acta haematologica, 2002, Volume: 108, Issue:1

    Topics: Adult; Aged; CD18 Antigens; Cell Adhesion; Clone Cells; Escherichia coli; Female; Flow Cytometry; Ge

2002
Acute myeloid leukemia (AML) having evolved from essential thrombocythemia (ET): distinctive chromosome abnormalities in patients treated with pipobroman or hydroxyurea.
    Leukemia, 2002, Volume: 16, Issue:10

    Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Chromosome Aberrations; Female; Humans; H

2002
Spinal meningioma during hydroxyurea therapy. A paradoxycal case report.
    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2002, Volume: 23, Issue:3

    Topics: Aged; Antineoplastic Agents; Cervical Vertebrae; Female; Humans; Hydroxyurea; Laminectomy; Magnetic

2002
Erythromelalgia due to essential thrombocythemia.
    Transfusion, 2002, Volume: 42, Issue:10

    Topics: Aged; Amputation, Surgical; Anticoagulants; Combined Modality Therapy; Erythromelalgia; Female; Fing

2002
Leg ulcers and hydroxyurea: report of three cases with essential thrombocythemia.
    International journal of dermatology, 2002, Volume: 41, Issue:12

    Topics: Aged; Antineoplastic Agents; Dose-Response Relationship, Drug; Female; Humans; Hydroxyurea; Leg Ulce

2002
Emergence of Philadelphia positive chronic myeloid leukaemia during treatment with hydroxyurea for Philadelphia negative essential thrombocythaemia.
    European journal of haematology, 2003, Volume: 70, Issue:4

    Topics: Antineoplastic Agents; Bone Marrow Examination; Humans; Hydroxyurea; Interferon-alpha; Karyotyping;

2003
Pseudothrombocytopenia as a pitfall in the treatment of essential thrombocythemia.
    European journal of haematology, 2003, Volume: 70, Issue:4

    Topics: Adult; Aged; Agglutinins; Anticoagulants; Artifacts; Autoantibodies; Citric Acid; Diagnosis, Differe

2003
Efficacy and safety of long-term use of hydroxyurea in young patients with essential thrombocythemia and a high risk of thrombosis.
    Blood, 2003, May-01, Volume: 101, Issue:9

    Topics: Adolescent; Adult; Anemia; Cohort Studies; Follow-Up Studies; Hemorrhage; Humans; Hydroxyurea; Incid

2003
Transition of essential thrombocythemia to megakaryoblastic leukemia after long-term therapy with sequential busulfan, pipobroman and hydroxyurea.
    Acta haematologica, 2003, Volume: 109, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Busulfan; Humans; Hydroxyurea; Leukemia

2003
Development of hairy cell leukemia in a patient treated with cytoreductive agents for essential thrombocythemia.
    Leukemia & lymphoma, 2003, Volume: 44, Issue:6

    Topics: Aged; Antigens, CD; Antineoplastic Agents; Bone Marrow Cells; Cladribine; Humans; Hydroxyurea; Leuke

2003
Associated thrombophilic defects in essential thrombocythaemia: their relationship with clinical manifestations.
    Thrombosis research, 2003, Volume: 112, Issue:3

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amino Acid Substitution; Antithrombin III; Child; Female

2003
Towards a rational treatment of essential thrombocythemia, despite limited evidence and old prejudices.
    Haematologica, 2004, Volume: 89, Issue:2

    Topics: Adult; Cohort Studies; Disease Progression; Evidence-Based Medicine; Expert Testimony; Female; Hemor

2004
Essential thrombocythaemia in two dogs.
    Tijdschrift voor diergeneeskunde, 2004, Jun-01, Volume: 129, Issue:11

    Topics: Animals; Antisickling Agents; Bone Marrow Cells; Dog Diseases; Dogs; Dose-Response Relationship, Dru

2004
The effects of hydroxyurea on PRV-1 expression in patients with essential thrombocythemia and polycythemia vera.
    Haematologica, 2004, Volume: 89, Issue:10

    Topics: Aged; Aged, 80 and over; Biomarkers; Computer Systems; Female; GPI-Linked Proteins; Humans; Hydroxyu

2004
Cytoreductive therapy for patients with essential thrombocythemia at high risk of thromboembolic complications. The difficult choice of the optimal drug.
    Haematologica, 2004, Volume: 89, Issue:11

    Topics: Adult; Humans; Hydroxyurea; Middle Aged; Pipobroman; Platelet Aggregation Inhibitors; Prognosis; Ris

2004
Hydroxyurea-induced hemolytic anemia in a patient with essential thrombocythemia.
    American journal of hematology, 2004, Volume: 77, Issue:4

    Topics: Aged; Aged, 80 and over; Anemia, Hemolytic; Blood Cell Count; Erythrocyte Transfusion; Humans; Hydro

2004
[Choice of therapy and overall survival in patients with chronic myeloproliferative diseases].
    Voprosy onkologii, 2004, Volume: 50, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Busulfan;

2004
The indolent natural history of essential thrombocythemia: a challenge to new drug development.
    Mayo Clinic proceedings, 2005, Volume: 80, Issue:1

    Topics: Humans; Hydroxyurea; Thrombocythemia, Essential

2005
The Philadelphia translocation and pre-existing myeloproliferative disorders.
    British journal of haematology, 2005, Volume: 128, Issue:5

    Topics: Antineoplastic Agents; Benzamides; Humans; Hydroxyurea; Imatinib Mesylate; Leukemia, Myelogenous, Ch

2005
When and how to treat essential thrombocythemia.
    The New England journal of medicine, 2005, Jul-07, Volume: 353, Issue:1

    Topics: Antineoplastic Agents; Aspirin; Drug Therapy, Combination; Hemorrhage; Humans; Hydroxyurea; Leukemia

2005
Essential thrombocythemia in a child: diagnostic and therapeutic dilemma.
    Saudi medical journal, 2005, Volume: 26, Issue:11

    Topics: Biopsy, Needle; Blood Chemical Analysis; Bone Marrow Cells; Child; Follow-Up Studies; Humans; Hydrox

2005
[Essential thrombocythemia associated with incomplete type intestinal Behçet disease during hydroxyurea treatment].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2005, Volume: 46, Issue:10

    Topics: Aged; Behcet Syndrome; Biomarkers; HLA-B Antigens; HLA-B51 Antigen; Humans; Hydroxyurea; Male; Throm

2005
Leg ulcer in a patient associated with hydroxyurea therapy.
    International journal of dermatology, 2006, Volume: 45, Issue:2

    Topics: Alginates; Antineoplastic Agents; Bandages; Biguanides; Debridement; Glucuronic Acid; Hexuronic Acid

2006
Essential thrombocythemias without V617F JAK2 mutation are clonal hematopoietic stem cell disorders.
    Leukemia, 2006, Volume: 20, Issue:6

    Topics: Adolescent; Adult; Aged; Clone Cells; Female; Follow-Up Studies; Hematopoietic Stem Cells; Humans; H

2006
Emergence of chronic myelogenous leukemia in a patient with primary thrombocythemia and absence of BCR/ABL rearrangement.
    Cancer genetics and cytogenetics, 2006, Volume: 167, Issue:1

    Topics: Aged; Antineoplastic Agents; Benzamides; Blood Platelets; Bone Marrow Cells; Cells, Cultured; Chromo

2006
Anagrelide: new drug. Essential thrombocythaemia: further evaluation needed for this last-resort treatment.
    Prescrire international, 2006, Volume: 15, Issue:83

    Topics: Clinical Trials as Topic; Cost-Benefit Analysis; Drug Approval; Drugs, Investigational; Europe; Huma

2006
Effects of anagrelide on megakaryopoiesis and platelet production.
    Seminars in thrombosis and hemostasis, 2006, Volume: 32, Issue:4 Pt 2

    Topics: Animals; Antineoplastic Agents; Apoptosis; Bone Marrow; Cell Differentiation; Drug Evaluation; Human

2006
Acute biphenotypic leukemia arising in a patient with essential thrombocythemia.
    American journal of hematology, 2006, Volume: 81, Issue:8

    Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Chromosomes,

2006
Hydroxyurea therapy increases plasma erythropoietin in patients with essential thrombocythaemia or polycythaemia vera.
    Clinical and laboratory haematology, 2006, Volume: 28, Issue:4

    Topics: Aged; Aged, 80 and over; Blood Platelets; Erythropoietin; Female; Humans; Hydroxyurea; Male; Middle

2006
Coronary artery intervention after cytostatics treatment in unstable angina patient with essential thrombocythemia. A case report and literature review.
    The Korean journal of internal medicine, 2006, Volume: 21, Issue:2

    Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Humans; Hydroxyurea; Male; Middle Aged; Quinazolin

2006
Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients.
    Leukemia, 2007, Volume: 21, Issue:2

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Cell Transformation, N

2007
Multiple granulocytic sarcomas in essential thrombocythemia.
    International journal of hematology, 2006, Volume: 84, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Chromosome Deletion; Chromosomes,

2006
A unified definition of clinical resistance/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group.
    Leukemia, 2007, Volume: 21, Issue:2

    Topics: Antineoplastic Agents; Consensus Development Conferences as Topic; Drug Resistance; Humans; Hydroxyu

2007
Association of essential thrombocythemia and chronic lymphocytic leukemia: absence of the V617F JAK2 mutation in the lymphoid compartment.
    American journal of hematology, 2007, Volume: 82, Issue:6

    Topics: Female; Humans; Hydroxyurea; Janus Kinase 2; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoprolifera

2007
Hydroxyurea therapy: a rare cause of reversible azoospermia.
    International urology and nephrology, 2007, Volume: 39, Issue:3

    Topics: Adult; Azoospermia; Erythromelalgia; Humans; Hydroxyurea; Male; Nucleic Acid Synthesis Inhibitors; S

2007
Essential thrombocythemia in a child with elevated thrombopoietin concentrations and skeletal anomalies.
    Pediatric blood & cancer, 2008, Volume: 50, Issue:4

    Topics: Aspirin; Bone and Bones; Child, Preschool; Enzyme Inhibitors; Female; Humans; Hydroxyurea; Male; Mot

2008
[Cerebral venous thrombosis secondary to essential thrombocythemia].
    Revue neurologique, 2007, Volume: 163, Issue:5

    Topics: Adolescent; Allopurinol; Brain; Cerebral Veins; Drug Therapy, Combination; Enzyme Inhibitors; Female

2007
[Case of erythromelalgia due to essential thrombocythemia].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2007, Volume: 48, Issue:5

    Topics: Aged; Aspirin; Debridement; Diagnosis, Differential; Erythromelalgia; Female; Humans; Hydroxyurea; T

2007
Essential thrombocythaemia treatment options: addressing patient-specific needs.
    European journal of haematology. Supplementum, 2007, Issue:68

    Topics: Disease Management; Health Services Needs and Demand; Humans; Hydroxyurea; Interferon alpha-2; Inter

2007
New consensus: a unified definition of clinical resistance and/or intolerance to hydroxyurea in essential thrombocythaemia.
    European journal of haematology. Supplementum, 2007, Issue:68

    Topics: Drug Resistance; Humans; Hydroxyurea; Platelet Count; Thrombocythemia, Essential

2007
Implications of the consensus definition of clinical resistance and intolerance to hydroxyurea for clinical practice.
    European journal of haematology. Supplementum, 2007, Issue:68

    Topics: Disease Management; Drug Resistance; Humans; Hydroxyurea; Leg Ulcer; Platelet Count; Thrombocythemia

2007
Options in the management of essential thrombocythaemia.
    European journal of haematology. Supplementum, 2007, Issue:68

    Topics: Age Factors; Disease Management; Humans; Hydroxyurea; Interferons; Platelet Count; Quinazolines; Ris

2007
Practical approach to treating essential thrombocythaemia: case studies.
    European journal of haematology. Supplementum, 2007, Issue:68

    Topics: Adult; Aspirin; Disease Management; Female; Humans; Hydroxyurea; Interferon-alpha; Leg Ulcer; Male;

2007
Prevention of thrombosis in polycythemia vera and essential thrombocythemia.
    Haematologica, 2008, Volume: 93, Issue:3

    Topics: Arterial Occlusive Diseases; Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Humans;

2008
Acute myocardial infarction: an unusual presentation of essential thrombocytosis in a 17-year-old man.
    Clinical advances in hematology & oncology : H&O, 2008, Volume: 6, Issue:2

    Topics: Adolescent; Female; Humans; Hydroxyurea; Myocardial Infarction; Nucleic Acid Synthesis Inhibitors; P

2008
[Recent trends in therapy of chronic myeloproliferative disorders].
    Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 1993, Jul-10, Volume: 82, Issue:7

    Topics: Alkylating Agents; Aspirin; Humans; Hydroxyurea; Interferons; Pipobroman; Prognosis; Thrombocythemia

1993
[Essential thrombocythemia--clinical course from personal material].
    Polskie Archiwum Medycyny Wewnetrznej, 1994, Volume: 92, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Busulfan; Female; Humans; Hydroxyurea; Interferon-alpha; Male; Middl

1994
Pregnancy after treatment with hydroxyurea in a patient with primary thrombocythaemia and a history of recurrent abortion.
    Journal of clinical pathology, 1994, Volume: 47, Issue:8

    Topics: Abortion, Habitual; Adult; Blood Platelets; Female; Humans; Hydroxyurea; Pregnancy; Pregnancy Compli

1994
Essential thrombocythemia: a relative benign long-term course.
    Israel journal of medical sciences, 1993, Volume: 29, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Busulfan; Female; Follow-Up Studies; Hemoglobins; Humans

1993
Acute myeloid leukemia evolving from essential thrombocythemia in two patients treated with hydroxyurea.
    American journal of hematology, 1996, Volume: 51, Issue:2

    Topics: Acute Disease; Antineoplastic Agents; Humans; Hydroxyurea; Leukemia, Myeloid; Male; Middle Aged; Thr

1996
Unwanted side effect of hydroxyurea.
    Annals of hematology, 1996, Volume: 72, Issue:2

    Topics: Female; Fever; Humans; Hydroxyurea; Middle Aged; Thrombocythemia, Essential

1996
Transformation of essential thrombocythaemia to T cell acute lymphoblastic leukaemia.
    Leukemia & lymphoma, 1996, Volume: 20, Issue:3-4

    Topics: Aged; Aged, 80 and over; Female; Humans; Hydroxyurea; Immunophenotyping; Leukemia-Lymphoma, Adult T-

1996
Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
    American journal of hematology, 1996, Volume: 52, Issue:1

    Topics: Acute Disease; Anemia, Refractory, with Excess of Blasts; Busulfan; Cell Transformation, Neoplastic;

1996
Essential thrombocythemia and central retinal vein occlusion with neovascular glaucoma.
    American journal of ophthalmology, 1996, Volume: 121, Issue:6

    Topics: Adrenergic beta-Antagonists; Antisickling Agents; Aspirin; Bone Marrow; Fluorescein Angiography; Fun

1996
[A lower-leg ulcer during hydroxyurea therapy for essential thrombocythemia].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1996, Volume: 23, Issue:7

    Topics: Foot Ulcer; Humans; Hydroxyurea; Male; Middle Aged; Platelet Aggregation Inhibitors; Thrombocythemia

1996
Clonality analysis of hematopoiesis in essential thrombocythemia: advantages of studying T lymphocytes and platelets.
    Blood, 1997, Jan-01, Volume: 89, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Platelets; Dosage Compensation, Genetic; Female; G

1997
[Hypertriglyceridemia following treatment with interferon alpha in essential thrombocythemia].
    Investigacion clinica, 1996, Volume: 37, Issue:3

    Topics: Adult; Allopurinol; Female; Humans; Hydroxyurea; Hypertriglyceridemia; Immunologic Factors; Interfer

1996
The paradox of bleeding and thrombosis in thrombocythemia: is von Willebrand factor the link?
    Seminars in thrombosis and hemostasis, 1997, Volume: 23, Issue:4

    Topics: Aged; Alkylating Agents; Aspirin; Erythromelalgia; Female; Fibrinolytic Agents; Hemorrhage; Hemorrha

1997
Busulfan versus hydroxyurea in the treatment of polycythemia vera (PV) and essential thrombocythemia (ET)
    American journal of clinical oncology, 1998, Volume: 21, Issue:1

    Topics: Antineoplastic Agents; Busulfan; Humans; Hydroxyurea; Immunosuppressive Agents; Polycythemia Vera; R

1998
Treatment of myeloproliferative disorders with hydroxyurea: effects on red blood cell geometry and deformability.
    Blood, 1998, May-15, Volume: 91, Issue:10

    Topics: Aged; Animals; Antineoplastic Agents, Alkylating; Cats; Cell Size; Erythrocyte Deformability; Erythr

1998
Plasma erythropoietin by high-detectability immunoradiometric assay in untreated and treated patients with polycythaemia vera and essential thrombocythaemia.
    European journal of haematology, 1998, Volume: 60, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Erythropoietin; Female; Hemoglobins; Humans; Hydroxyurea; Immunoradi

1998
Is hydroxyurea leukemogenic in essential thrombocythemia?
    Blood, 1998, Aug-15, Volume: 92, Issue:4

    Topics: Acute Disease; Antineoplastic Agents, Alkylating; Bone Marrow; Busulfan; Chromosome Aberrations; Chr

1998
Acute coronary disease in essential thrombocythemia and polycythemia vera.
    Journal of internal medicine, 1998, Volume: 244, Issue:1

    Topics: Adult; Aged; Aging; Antisickling Agents; Aspirin; Female; Follow-Up Studies; Humans; Hydroxyurea; Ma

1998
[Hyperalgesic malleolar ulcer: recovery on the withdrawal of hydroxyurea].
    La Revue de medecine interne, 1998, Volume: 19, Issue:5

    Topics: Ankle; Enzyme Inhibitors; Female; Humans; Hydroxyurea; Hyperalgesia; Hyperpigmentation; Leg Ulcer; M

1998
[A case of coronary artery bypass surgery using left internal thoracic artery and right gastroepiploic artery for a patient with essential thrombocythemia].
    The Japanese journal of thoracic and cardiovascular surgery : official publication of the Japanese Association for Thoracic Surgery = Nihon Kyobu Geka Gakkai zasshi, 1998, Volume: 46, Issue:8

    Topics: Aged; Angina Pectoris; Coronary Artery Bypass; Fatal Outcome; Humans; Hydroxyurea; Male; Omentum; St

1998
Nail changes after chemotherapy.
    Haematologica, 1998, Volume: 83, Issue:8

    Topics: Alkylating Agents; Female; Humans; Hydroxyurea; Melanosis; Middle Aged; Nail Diseases; Thrombocythem

1998
Anagrelide-induced relapse of a hydroxyurea-induced leg ulcer in a patient with primary thrombocythemia.
    Mayo Clinic proceedings, 1998, Volume: 73, Issue:11

    Topics: Aged; Antineoplastic Agents; Female; Fibrinolytic Agents; Humans; Hydroxyurea; Leg Ulcer; Platelet A

1998
Hydroxyurea-induced fever and hepatitis.
    Australian and New Zealand journal of medicine, 1998, Volume: 28, Issue:5

    Topics: Aged; Chemical and Drug Induced Liver Injury; Female; Fever; Humans; Hydroxyurea; Male; Middle Aged;

1998
Patients with essential thrombocythemia do not express BCR-ABL transcripts.
    Blood, 1999, Apr-01, Volume: 93, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Bone Marrow; Enzyme Inhibitors; Female; Fusion Proteins, bcr-abl; Ge

1999
Hydroxyurea-induced acute interstitial pneumonitis in a patient with essential thrombocythemia.
    Annals of hematology, 1999, Volume: 78, Issue:4

    Topics: Humans; Hydroxyurea; Lung Diseases, Interstitial; Male; Middle Aged; Radiography, Thoracic; Thromboc

1999
Leukemia and myelodysplasia in patients with essential thrombocythemia treated with cytotoxic agents.
    Haematologica, 1999, Volume: 84, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Busulfan; Female; Follow-Up Studies; Humans;

1999
[Essential thrombocythemia in transformation from myelodysplastic syndrome to acute myeloid leukemia with inv(3) after treatment for gastric cancer].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2000, Volume: 41, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosome Inversion; Chromosomes, Human, Pair

2000
Essential thrombocythemia in young adults: major thrombotic complications and complications during pregnancy--a follow-up study in 68 patients.
    Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2000, Volume: 6, Issue:1

    Topics: Acute Disease; Adult; Age Factors; Arteriosclerosis; Aspirin; Busulfan; Cohort Studies; Disease-Free

2000
Leukemia and myelodysplasia effect of multiple cytotoxic therapy in essential thrombocythemia.
    Leukemia & lymphoma, 2000, Volume: 37, Issue:3-4

    Topics: Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Busulfan; Fatal Outcome; Female; Humans; Hydro

2000
Essential thrombocythemia and recurrent myocardial infarction.
    Clinical and laboratory haematology, 2000, Volume: 22, Issue:3

    Topics: Angina, Unstable; Female; Humans; Hydroxyurea; Middle Aged; Myocardial Infarction; Platelet Count; R

2000
Acquired pericentric inversion of chromosome 9 in essential thrombocythemia.
    Human genetics, 2000, Volume: 106, Issue:6

    Topics: Bone Marrow Examination; Cells, Cultured; Centromere; Chromosome Inversion; Chromosomes, Human, Pair

2000
Essential thrombocythemia transformed to acute myelogenous leukemia with t(3;17)(p24; q12), del(5)(q13q34) after treatment with carboquone and hydroxyurea.
    Japanese journal of clinical oncology, 2000, Volume: 30, Issue:7

    Topics: Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Carbazilquinone; Chromosomes, Human, P

2000
Hydroxyurea as a cause of drug fever.
    Acta haematologica, 2000, Volume: 104, Issue:1

    Topics: Female; Fever; Humans; Hydroxyurea; Middle Aged; Thrombocythemia, Essential

2000
The predictive value of vascular risk factors and gender for the development of thrombotic complications in essential thrombocythemia.
    Annals of hematology, 2001, Volume: 80, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Arterial Occlusive Diseases; Blood Platelets; Busulfan; Female; Huma

2001
[Drug-induced fever caused by hydroxyurea. Apropos of 3 new cases].
    Annales de medecine interne, 1998, Volume: 149, Issue:2

    Topics: Aged; Antineoplastic Agents; Enzyme Inhibitors; Female; Fever; Humans; Hydroxyurea; Male; Middle Age

1998
[How should patients with essential thrombocythemia be treated?].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2001, Volume: 42, Issue:6

    Topics: Clinical Trials as Topic; Enzyme Inhibitors; Humans; Hydroxyurea; Leukemia; Platelet Aggregation Inh

2001
Translocation t(4; 6)(q21; q27) in a case of primary thrombocythaemia in transformation.
    Clinical and laboratory haematology, 2001, Volume: 23, Issue:4

    Topics: Aged; Cell Transformation, Neoplastic; Chromosomes, Human, Pair 4; Chromosomes, Human, Pair 6; Fatal

2001
Second malignancies in patients with essential thrombocythaemia.
    British journal of haematology, 2002, Volume: 116, Issue:4

    Topics: Adult; Aged; Antineoplastic Agents; Busulfan; Female; Follow-Up Studies; Humans; Hydroxyurea; Male;

2002
Splenectomy in a case of splenic vein thrombosis unmasks essential thrombocythemia.
    Clinical and laboratory haematology, 2002, Volume: 24, Issue:2

    Topics: Adult; Hematemesis; Humans; Hydroxyurea; Hypertension, Portal; Ischemic Attack, Transient; Male; Pla

2002
Four pregnancies in two patients with essential thrombocythaemia--a case report.
    Annals of the Academy of Medicine, Singapore, 2002, Volume: 31, Issue:3

    Topics: Adult; Aspirin; Combined Modality Therapy; Cyclooxygenase Inhibitors; Female; Fetal Death; Humans; H

2002
Leukemic transformation with trisomy 8 in essential thrombocythemia: a report of four cases.
    European journal of haematology, 2002, Volume: 68, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Bone Marrow; Busulfan; Cell Transformation, Neoplastic; Chromosomes,

2002
[Clinical experience of urological surgery of the patients with hemostatic disorder or hemolytic disease].
    Hinyokika kiyo. Acta urologica Japonica, 1992, Volume: 38, Issue:11

    Topics: Adult; Aged; Blood Coagulation Factors; Blood Transfusion, Autologous; Child; Child, Preschool; Fact

1992
Reversal of delirium associated with essential thrombocythemia by antiplatelet therapy.
    Psychosomatics, 1992,Spring, Volume: 33, Issue:2

    Topics: Aged; Aspirin; Delirium; Female; Humans; Hydroxyurea; Platelet Aggregation Inhibitors; Platelet Coun

1992
Essential thrombocythemia--clinical features, therapy and follow-up of 12 cases.
    Leukemia, 1992, Volume: 6 Suppl 3

    Topics: Aged; Female; Humans; Hydroxyurea; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Platelet

1992
[Value of the combination of interferon alpha with hydroxyurea in essential thrombocythemia].
    Presse medicale (Paris, France : 1983), 1991, Sep-28, Volume: 20, Issue:30

    Topics: Adult; Drug Therapy, Combination; Female; Humans; Hydroxyurea; Interferon Type I; Thrombocythemia, E

1991
Clinical significance of serum pro-collagen III in chronic myeloproliferative disorders.
    European journal of haematology, 1990, Volume: 45, Issue:5

    Topics: Aged; Bloodletting; Humans; Hydroxyurea; Myeloproliferative Disorders; Polycythemia; Polycythemia Ve

1990
Myelodysplastic syndrome and secondary acute leukemia after treatment of essential thrombocythemia with hydroxyurea.
    American journal of hematology, 1990, Volume: 33, Issue:2

    Topics: Acute Disease; Female; Humans; Hydroxyurea; Leukemia; Middle Aged; Myelodysplastic Syndromes; Thromb

1990
Management of polycythaemia vera, essential thrombocythaemia and myelofibrosis with hydroxyurea.
    European journal of haematology, 1988, Volume: 41, Issue:4

    Topics: Drug Evaluation; Humans; Hydroxyurea; Platelet Count; Polycythemia Vera; Primary Myelofibrosis; Thro

1988